Williams Obstetrics, 24th Edition

CHAPTER 59. Connective-Tissue Disorders

IMMUNE-MEDIATED CONNECTIVE-TISSUE DISEASES

SYSTEMIC LUPUS ERYTHEMATOSUS

ANTIPHOSPHOLIPID ANTIBODY SYNDROME

RHEUMATOID ARTHRITIS

SYSTEMIC SCLEROSIS—SCLERODERMA

VASCULITIS SYNDROMES

INFLAMMATORY MYOPATHIES

HEREDITARY CONNECTIVE-TISSUE DISORDERS

Connective-tissue disorders, which are also termed collagen-vascular disorders, have two basic underlying causes. First are the autoantibody-mediated immune-complex diseases in which connective-tissue damage is caused by deposition of immune complexes in specific organ(s) or tissue sites. Because these are manifest by sterile inflammation—predominately of the skin, joints, blood vessels, and kidneys—they are referred to as rheumatic diseases. Many of these immune-complex diseases are more prevalent in women, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis, and a host of vasculitis syndromes. Second are the inherited disorders of bone, skin, cartilage, blood vessels, and basement membranes. Some examples include Marfan syndrome, osteogenesis imperfecta, and Ehlers-Danlos syndrome.

IMMUNE-MEDIATED CONNECTIVE-TISSUE DISEASES

These disorders can be separated into those associated with and those without autoantibody formation. So-called rheumatoid factor (RF) is an autoantibody found in many autoimmune inflammatory conditions such as SLE, rheumatoid arthritis, systemic sclerosis (scleroderma), mixed connective-tissue disease, dermatomyositis, polymyositis, and various vasculitis syndromes. The RF-seronegative spondyloarthropathies are strongly associated with expression of the HLA-B27 antigen and include ankylosing spondylitis, psoriatic arthritis, Reiter disease, and other arthritis syndromes.

Pregnancy may mitigate activity in some of these syndromes as a result of the immunosuppression that also allows successful engraftment of fetal and placental tissues. These changes are discussed in detail in Chapters 4 and 5 (p. 56). One example is pregnancy-induced predominance of T2 helper cells compared with cytokine-producing T1 helper cells (Keeling, 2009). Pregnancy hormones alter immune cells, for example, estrogens upregulate and androgens downregulate T-cell response, and progesterone is immunosuppressive (Cutolo, 2006; Häupl, 2008a; Robinson, 2012).

Some immune-mediated diseases may either be caused or activated as a result of previous pregnancies. To explain, fetal cells and free fetal DNA are detectable in maternal blood beginning early in pregnancy (Simpson, 2013; Sitar, 2005; Waldorf, 2008). Fetal cell microchimerism is the persistence of fetal cells in the maternal circulation and organs following pregnancy. These persistent fetal cells may stimulate autoantibodies, or they may become engrafted in maternal tissues. This raises the possibility that fetal cell microchimerism is related to the predilection of autoimmune disorders for women (Adams, 2004; Lissauer, 2009). Evidence for this includes findings of fetal stem cells engrafted in maternal tissues in women with autoimmune thyroiditis and systemic sclerosis (Jimenez, 2005; Srivatsa, 2001). Such microchimerism has also been described in women with SLE and those with rheumatoid arthritis-associated HLA alleles (Johnson, 2001; Lee, 2010; Rak, 2009a). Similarly, engrafted maternal cells may provoke autoimmune conditions in a woman’s offspring (Ye, 2012). Perhaps related, women with SLE have a 0.6 male:female offspring ratio suggesting excessive male fetal loss in these women (Aggarwal, 2013).

image Systemic Lupus Erythematosus

Lupus is a heterogeneous autoimmune disease with a complex pathogenesis that results in interactions between susceptibility genes and environmental factors (Hahn, 2012; Tsokos, 2011). Immune system abnormalities include overactive B lymphocytes that are responsible for autoantibody production. These result in tissue and cellular damage when autoantibodies or immune complexes are directed at one or more cellular nuclear components (Tsokos, 2011). In addition, immunosuppression is impaired, including regulatory T-cell function (Tower, 2013). Some autoantibodies produced in patients with lupus are shown in Table 59-1.

TABLE 59-1. Some Autoantibodies Produced in Patients with Systemic Lupus Erythematosus (SLE)

image

Almost 90 percent of lupus cases are in women, and its prevalence in those of childbearing age is approximately 1 in 500 (Lockshin, 2000). Accordingly, the disease is encountered relatively frequently during pregnancy. The 10-year survival rate is 70 to 90 percent (Hahn, 2012; Tsokos, 2011). Infection, lupus flares, end-organ failure, hypertension, stroke, and cardiovascular disease account for most deaths.

Genetic influences are implicated by a higher concordance with monozygotic compared with dizygotic twins—25 versus 2 percent, respectively. Moreover, there is a 10-percent frequency in patients with one affected family member. The relative risk of disease is increased if there is inheritance of the “autoimmunity gene” on chromosome 16 that predisposes to SLE, rheumatoid arthritis, Crohn disease, and psoriasis (Hahn, 2012). Susceptibility genes such as HLA-A1, B8, DR3, DRB1, and TET3 explain only a portion of the genetic heritability (Hom, 2008; Tsokos, 2011; Yang, 2013).

Clinical Manifestations and Diagnosis

Lupus is notoriously variable in its presentation, course, and outcome (Table 59-2). Findings may be confined initially to one organ system, and others become involved later. Or, the disease may first manifest with multisystem involvement. Common findings are malaise, fever, arthritis, rash, pleuropericarditis, photosensitivity, anemia, and cognitive dysfunction. At least half of patients have renal involvement. There is evidence that lupus is associated with decline in attention, memory, and reasoning (Kozora, 2008). Although Libman-Sacks endocarditis was described with lupus, it is likely due to presence of subsequently discussed anticardiolipin antibodies (Hojnik, 1996).

TABLE 59-2. Clinical Manifestations of Systemic Lupus Erythematosus

image

Identification of antinuclear antibodies (ANA) is the best screening test. However, a positive result is not specific for lupus. For example, low titers are found in normal individuals, other autoimmune diseases, acute viral infections, and chronic inflammatory processes. Several drugs can also cause a positive reaction. Antibodies to double-stranded DNA (dsDNA) and to Smith (Sm) antigens are relatively specific for lupus, whereas other antibodies are not (see Table 59-1). Although hundreds of autoantibodies have been described in SLE, only a few have been shown to participate in tissue injury (Sherer, 2004; Tsokos, 2011). Microarray profiles are being developed for customized and more accurate SLE diagnoses (Lin, 2013; Yeste, 2013).

Anemia develops frequently, and there may be leukopenia and thrombocytopenia. Proteinuria and casts are found in the half of patients with glomerular lesions. Lupus nephritis can also cause renal insufficiency, which is more common if there are antiphospholipid antibodies (Moroni, 2004). Other laboratory findings include false-positive syphilis serology, prolonged partial thromboplastin time, and higher rheumatoid factor levels. Elevated serum D-dimer levels often follow a flare or infection, but unexplained persistent elevations are associated with a high risk for thrombosis (Wu, 2008).

The diagnostic criteria for SLE are listed in Table 59-3. If any four or more of these 11 criteria are present, serially or simultaneously, the diagnosis of lupus is made.

TABLE 59-3. Criteria of the American Rheumatism Association for Systemic Lupus Erythematosus (SLE)

image

Importantly, numerous drugs can induce a lupus-like syndrome. These include procainamide, quinidine, hydralazine, α-methyldopa, phenytoin, and phenobarbital. Drug-induced lupus is rarely associated with glomerulonephritis and usually regresses when the medication is discontinued (Rubin, 1997).

Lupus and Pregnancy

Of nearly 16.7 million pregnancies in the United States from 2000 to 2003, 13,555 were complicated by lupus—an incidence of approximately 1 in 1250 pregnancies (Clowse, 2008). During the past several decades, pregnancy outcomes in women with SLE have improved remarkably. Important factors for pregnancy outcome include whether disease is active at the beginning of pregnancy, age and parity, coexistence of other medical or obstetrical disorders, and whether antiphospholipid antibodies are detected (p. 1173). There is evidence that newly diagnosed lupus during pregnancy tends to be severe (Zhao, 2013).

During pregnancy, lupus improves in a third of women, remains unchanged in a third, and worsens in the remaining third. Thus, in any given pregnancy, the clinical condition can worsen or flare without warning (Khamashta, 1997). Petri (1998) reported a 7-percent risk of major morbidity during pregnancy. Women who have confined cutaneous lupus do not usually have adverse outcomes (Hamed, 2013). Frequent complications in a cohort of 13,555 women with SLE during pregnancy are shown in Table 59-4. The maternal mortality and severe morbidity rate was 325 per 100,000. In a review of 13 studies with 17 maternal deaths attributable to SLE and lupus nephritis, all occurred in those with active disease (Ritchie, 2012).

TABLE 59-4. Complications in 13,555 Pregnancies in Women with Systemic Lupus Erythematosus

image

From the foregoing, it is certain that lupus can be life threatening for both mother and fetus. Generally speaking, pregnancy outcome is best in those women in whom: (1) lupus activity has been quiescent for at least 6 months before conception; (2) there is no lupus nephritis manifest by proteinuria or renal dysfunction; (3) there is no evidence of the antiphospholipid antibody syndrome or lupus anticoagulant; and (4) superimposed preeclampsia does not develop (Peart, 2014; Stojan, 2012).

Lupus Nephritis. Active nephritis has been associated with particularly bad pregnancy outcomes, although these have improved remarkably during the past 30 years (Moroni, 2005; Stojan, 2012). Women with renal disease have a high incidence of gestational hypertension and preeclampsia. However, if their disease remains in remission, they usually have good pregnancy outcomes (Huong, 2001; Moroni, 2002). Of the 125 pregnancies reported by Lockshin (1989), 63 percent of women with preexisting renal disease developed preeclampsia compared with only 14 percent of those without underlying renal disease. Moroni and Ponticelli (2005) reviewed results from a total of 309 pregnancies complicated by established lupus nephritis. Of these, 30 percent suffered a flare, and 40 percent of these had associated renal insufficiency. The maternal mortality rate was 1.3 percent.

In two studies describing pregnancy outcomes in women with lupus nephritis, Wagner and coworkers (2009) compared outcomes of 58 women cared for during 90 pregnancies at the Mayo Clinic. Active nephritis was associated with a significantly higher incidence of maternal complications compared with women without nephritis—57 versus 11 percent. Quiescent nephritis had a nonsignificant effect on preeclampsia rates compared with lupus patients without renal impairment. The fetal death rate with active maternal nephritis was 35 percent compared with 9 percent in those with quiescent nephritis. In another study, Imbasciati and associates (2009) described outcomes in 113 pregnancies in 81 women with known lupus nephritis. During a third of pregnancies, there was a renal flare. After excluding nine miscarriages, of the 104 remaining pregnancies, a third were delivered preterm, a third of infants weighed < 2500 g, and the perinatal mortality rate was 6 percent.

Most recommend continuation of immunosuppressive therapy for nephritis during pregnancy. It is not clear whether the dose should be increased peripartum. Although it is often stated that this is the time that activation or exacerbations are most likely to develop, the evidence is not conclusive.

Lupus versus Preeclampsia-Eclampsia. Chronic hypertension complicates up to 30 percent of pregnancies in women with SLE (Egerman, 2005). And as discussed, preeclampsia is common, and superimposed preeclampsia is encountered even more often in those with nephritis or antiphospholipid antibodies (Bertsias, 2008). It may be difficult, if not impossible to differentiate lupus nephropathy from severe preeclampsia if the kidney is the only involved organ (Petri, 2007). Central nervous system involvement with lupus may culminate in convulsions similar to those of eclampsia. Thrombocytopenia, with or without hemolysis, may further confuse the diagnosis because of its similarity to the hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome. Management is identical to that for preeclampsia-eclampsia, described in Chapter 40 (p. 749).

Management During Pregnancy

Lupus management consists primarily of monitoring maternal clinical and laboratory conditions as well as fetal well-being (Lateef, 2012). Pregnancy-induced thrombocytopenia and proteinuria resemble lupus disease activity, and the identification of a lupus flare is confounded by the increase in facial and palmar erythema of normal pregnancy (Lockshin, 2003). Some authorities have advocated a number of numerical scales to emphasize ongoing disease activity. Components are weighted for severity, both with the SLE-Pregnancy Disease Activity Index (SLEPDAI) and with the Lupus Activity Index (Buyon, 1999; Ruiz-Irastorza, 2004). We have not found these to be useful.

Lupus activity monitoring and identification of lupus flares by various laboratory techniques has been recommended. The sedimentation rate may be misleading because of pregnancy-induced hyperfibrinogenemia. Serum complement levels are also normally increased in pregnancy (Chap. 4p. 56 and Appendixp. 1291). And, although falling or low levels of complement components C3, C4, and CH50 are more likely to be associated with active disease, higher levels provide no assurance against disease activation. Our experiences, as well as those of Varner and colleagues (1983) and Lockshin and Druzin (1995), are that there is no correlation between clinical manifestations of disease and complement levels.

Serial hematological studies may detect changes in disease activity. Hemolysis is characterized by a positive Coombs test, anemia, reticulocytosis, and unconjugated hyperbilirubinemia. Thrombocytopenia, leukopenia, or both may develop. According to Lockshin and Druzin (1995), chronic thrombocytopenia in early pregnancy may be due to antiphospholipid antibodies. Later, thrombocytopenia may indicate preeclampsia.

Serum aminotransferase activity reflects hepatic involvement, as does a rise in serum bilirubin levels. Azathioprine therapy also may induce enzyme elevations. Urine is tested frequently to detect new-onset or worsening proteinuria. Overt proteinuria that persists is an ominous sign, even more so if accompanied by other evidence of the nephrotic syndrome or abnormal serum creatinine levels.

The fetus should be closely observed for adverse effects such as growth restriction and oligohydramnios. Many recommend screening for anti-SS-A (anti-Ro) and anti-SS-B (anti-La) antibodies, because of associated fetal complications described subsequently. As discussed in Chapter 17 (p. 335), antepartum fetal surveillance is done as outlined by the American College of Obstetricians and Gynecologists (2012a). Unless hypertension develops or there is evidence of fetal compromise or growth restriction, pregnancy is allowed to progress to term. Peripartum corticosteroids in “stress doses” are given to women who are taking these drugs or who recently have done so.

Pharmacological Treatment. There is no cure, and complete remissions are rare. Approximately a fourth of women have mild disease, which is not life threatening, but may be disabling because of pain and fatigue. Arthralgia and serositis can be managed by occasional doses of nonsteroidal antiinflammatory drugs (NSAIDs). However, chronic or large intermittent dosing is avoided due to pregnancy side effects with these drugs described in Chapter 12 (p. 247) (Briggs, 2011). Low-dose aspirin can be used throughout gestation. Severe disease is managed with corticosteroids such as prednisone, 1 to 2 mg/kg orally per day. After the disease is controlled, this dose is tapered to a daily morning dose of 10 to 15 mg. Corticosteroid therapy can result in the development of gestational diabetes.

Immunosuppressive agents such as azathioprine are beneficial in controlling active disease (Contreras, 2004; Hahn, 2012). In nonpregnant patients, these are usually reserved for lupus nephritis or disease that is corticosteroid resistant. Azathioprine has a good safety record during pregnancy (Fischer-Betz, 2013; Petri, 2007). Its recommended daily oral dose is 2 to 3 mg/kg. According to Buhimschi and Weiner (2009), cyclophosphamide is teratogenic, and although not usually recommended during pregnancy, severe disease may be treated after 12 weeks’ gestation. As discussed in Chapter 12 (p. 250), medications to be avoided include mycophenolate mofetil and methotrexate (Anderka, 2009; Briggs, 2011; Food and Drug Administration, 2008). In some situations, mycophenolate is the only treatment that achieves disease stability. In these cases, counseling regarding fetal risks is essential (Bramham, 2012).

Antimalarials help control skin disease. Although these agents cross the placenta, hydroxychloroquine has not been associated with congenital malformations. Because of the long half-life of antimalarials and because discontinuing therapy can precipitate a lupus flare, most recommend their continuation during pregnancy (Borden, 2001; Harris, 2002). Levy and associates (2001) randomly assigned 20 pregnant women to receive hydroxychloroquine or placebo and reported improved SLEPDAI scores with hydroxychloroquine.

When severe disease supervenes—usually a lupus flare—high-dose glucocorticoid therapy is given. Petri (2007) recommends pulse therapy consisting of methylprednisolone, 1000 mg given intravenously over 90 minutes daily for 3 days, then a return to maintenance doses if possible.

Perinatal Mortality and Morbidity

Adverse perinatal outcomes are increased significantly in pregnancies complicated by lupus. These include preterm delivery, fetal-growth restriction, stillbirths, and neonatal lupus syndrome (Madazli, 2014). Outcomes are worse with a lupus flare, significant proteinuria, or renal impairment, and with chronic hypertension, preeclampsia, or both (Aggarwal, 1999; Bramham, 2012; Scott, 2002; Wagner, 2009). The observations of Lee and coworkers (2009) are worrisome. In a mouse SLE model, they showed that autoantibodies directed against the N-methyl-D-aspartate neuroreceptor caused fetal neurotoxicity. This suggests an underlying etiology for the CNS manifestations and learning disorders in children of affected mothers. Ongoing work on anti-dsDNA antibodies has identified peptides that can protect target organs from antibody-mediated damage (Diamond, 2011).

The reasons at least partially responsible for adverse fetal consequences include decidual vasculopathy with placental infarction and decreased perfusion (Hanly, 1988; Lubbe, 1984). Placental pathology is discussed in more detail in Chapter 6 (p. 119).

Neonatal Lupus Syndrome. This unusual constellation is characterized by newborn skin lesions—lupus dermatitis; a variable number of hematological and systemic derangements; and occasionally congenital heart block (Boh, 2004; Lee, 2009). Although usually associated with anti-SS-A and -SS-B antibodies, McGeachy and Lam (2009) described an affected infant in whom only anti-ribonucleoprotein (RNP) antibodies were found. Thrombocytopenia and hepatic involvement are seen in 5 to 10 percent of affected infants. One report suggests that neonatal lupus may appear up to 4 weeks after birth (Stirnemann, 2002). Lockshin and colleagues (1988) prospectively followed 91 infants born to women with lupus. Eight were possibly affected—four had definite neonatal lupus and four had possible disease. Clinical manifestations, which include cutaneous lupus, thrombocytopenia, and autoimmune hemolysis, are transient and clear within a few months (Lee, 1984). This may not be so for congenital heart block. In subsequent offspring, the recurrence risk for neonatal lupus is up to 25 percent (Julkunen, 1993).

Congenital Heart Block. Fetal and neonatal heart block results from diffuse myocarditis and fibrosis in the region between the atrioventricular (AV) node and bundle of His. Buyon and associates (1993) reported that congenital heart block developed almost exclusively in fetuses of women with antibodies to the SS-A or SS-B antigens. These antibodies may also cause otherwise unexplained stillbirths (Ottaviani, 2004). Even in the presence of such antibodies, however, the incidence of myocarditis is only 2 to 3 percent but increases to 20 percent with a prior affected child (Bramham, 2012; Lockshin, 1988). Fetal cardiac monitoring should be performed between 18 and 26 weeks’ gestation in pregnancies with either of these antibodies. The cardiac lesion is permanent, and a pacemaker is generally necessary. Long-term prognosis is poor. Of 325 infants with cardiac neonatal lupus, nearly 20 percent died, and of these, a third were stillborn (Izmirly, 2011).

Maternal administration of corticosteroids, plasma exchange, or intravenous immunoglobulin have not been found to reduce the risk of congenital heart block. Corticosteroid therapy to treat fetal heart block has not been subjected to randomized trials. There is some evidence that early treatment may mitigate fetal myocarditis. Shinohara and coworkers (1999) reported no heart block in 26 neonates whose mothers received corticosteroids before 16 weeks’ gestation as part of SLE maintenance therapy. By contrast, 15 of 61 neonates with heart block were born to women in whom corticosteroid therapy was begun after 16 weeks for SLE exacerbation. Rein and colleagues (2009) followed 70 fetuses prospectively of mothers positive for anti-SS-A or -SS-B antibodies with serial fetal kinetocardiography (FKCG) to measure AV conduction time. In six fetuses, first-degree heart block developed at 21 to 34 weeks, and maternal dexamethasone treatment was associated with normalization of AV conduction in all within 3 to 14 days. There were no recurrences, and the infants all were well at a median follow-up of 4 years. However, as noted in Chapter 16 (p. 322), corticosteroids may be less effective for higher degrees of heart block. Moreover, potential benefit should be weighed against the risks of chronic corticosteroid treatment, including impaired fetal growth (Friedman, 2009).

Long-Term Prognosis and Contraception

In general, women with lupus and chronic vascular or renal disease may limit family size because of morbidity associated with the disease as well as increased adverse perinatal outcomes. Two large multicenter clinical trials have shown that combination oral contraceptives (COCs) did not increase the incidence of lupus flares (Petri, 2005; Sánchez-Guerrero, 2005). Still, the American College of Obstetricians and Gynecologists (2013) recommends that COC use be avoided in women who have nephritis, antiphospholipid antibodies, or vascular disease. Progestin-only implants and injections provide effective contraception with no known effects on lupus flares (Chabbert-Buffet, 2010). Concerns that intrauterine device (IUD) use and immunosuppressive therapy lead to increased infection rates in these patients are not evidenced-based. Tubal sterilization may be advantageous and is performed with greatest safety postpartum or whenever the disease is quiescent. These options are discussed in further detail in Chapters 38 and 39.

image Antiphospholipid Antibody Syndrome

Phospholipids are the main lipid constituents of cell and organelle membranes. There are proteins in plasma that associate noncovalently with these phospholipids. Antiphospholipid antibodies are directed against these phospholipids or phospholipid-binding proteins (Erkan, 2011; Giannakopoulos, 2013; Tsokos, 2011). This antibody group may be of IgG, IgM, and IgA classes, alone or in combination. Antiphospholipid antibodies are most common with lupus and other connective-tissue disorders, although a small proportion of otherwise normal women and men are found to have these antibodies in various forms.

The stimulus for autoantibody production is unclear, but it possibly is due to a preceding infection. The pathophysiology encountered in the antiphospholipid antibody syndrome—variably referred to as APAS or APS—is mediated by one or more of the following: (1) activation of various procoagulants, (2) inactivation of natural anticoagulants, (3) complement activation, and (4) inhibition of syncytiotrophoblast differentiation (Moutsopoulos, 2012; Tsokos, 2011). Clinically, these result in arterial or venous thromboses or pregnancy morbidity, and virtually every organ system may be involved as shown in Table 59-5.

TABLE 59-5. Some Clinical Features of Antiphospholipid Antibody Syndrome

Venous thrombosis—thromboembolism, thrombophlebitis, livedo reticularis

Arterial thrombosis—stroke, transient ischemic attack, Libman-Sacks cardiac vegetations, myocardial ischemia, distal extremity and visceral thrombosis and gangrene

Hematological—thrombocytopenia, autoimmune hemolytic anemia

Other—neurological manifestations, migraine headaches, epilepsy; renal artery, vein, or glomerular thrombosis; arthritis and arthralgia

Pregnancy—preeclampsia syndrome, recurrent miscarriage, fetal death

Data from Giannakopoulos, 2013; Moutsopoulos, 2012.

Central nervous system involvement is one of the most prominent clinical manifestations. In addition to cerebrovascular arterial and venous thrombotic events, there may be psychiatric features and even multiple sclerosis (Binder, 2010; Sanna, 2003). Renovascular involvement may lead to renal failure that may be difficult to differentiate from lupus nephritis (D’Cruz, 2009). Peripheral and visceral thromboses are also a feature. For example, Ahmed and associates (2009) reported a postpartum woman who developed spontaneous cecal perforation associated with a mesenteric vessel infarction. As discussed in Chapter 18 (p. 359), antiphospholipid antibodies have been associated with excessive pregnancy loss (Branch, 2010). These and other detrimental effects on pregnancy outcomes are discussed subsequently.

A small proportion of these patients develop the catastrophic antiphospholipid antibody syndrome—CAPS. This is defined as a rapidly progressive thromboembolic disorder simultaneously involving three or more organ systems or tissues (Moutsopoulos, 2012).

Specific Antiphospholipid Antibodies

Several autoantibodies have been described that are directed against a specific phospholipid or phospholipid-binding protein. First, β2-glycoprotein I—also known as apolipoprotein H—is a phospholipid-binding plasma protein that inhibits prothrombinase activity within platelets and inhibits ADP-induced platelet aggregation (Giannakopoulos, 2013; Shi, 1993). Thus, its normal action is to inhibit procoagulant binding and thereby prevent coagulation cascade activation. Logically, antibodies directed against β2-glycoprotein I would inhibit its anticoagulant activity and promote thrombosis. This is important from an obstetrical viewpoint because β2-glycoprotein I is expressed in high concentrations on the syncytiotrophoblastic surface. Complement activation may contribute to it pathogenesis (Avalos, 2009; Tsokos, 2011). Teleologically, this seems appropriate because the decidua intuitively should be a critical area to prevent coagulation that might result in intervillous space thrombosis. Another possibility is that β2-glycoprotein I may be involved in implantation, and it may result in pregnancy loss via an inflammatory mechanism (Iwasawa, 2012; Meroni, 2011).

Second, lupus anticoagulant (LAC) is a heterogeneous group of antibodies directed also against phospholipid-binding proteins. LAC induces prolongation in vitro of the prothrombin, partial thromboplastin, and Russell viper venom times (Feinstein, 1972). Thus, paradoxically, this so-called anticoagulant is actually powerfully thrombotic in vivo.

Last, there are anticardiolipin antibodies (ACAs). These are directed against one of the many phospholipid cardiolipins found in mitochondrial membranes and platelets.

Antibodies against Natural Anticoagulants

Antiphospholipid antibodies have also been described that are directed against the natural anticoagulant proteins C and S (Robertson, 2006). Another is directed against the anticoagulant protein annexin V, which is expressed in high concentrations by the syncytiotrophoblast (Chamley, 1999; Giannakopoulos, 2013). That said, criteria to diagnosis antiphospholipid-antibody syndrome require testing for elevated levels of the following antiphospholipid antibodies: LAC, ACA, and anti-β2 glycoprotein I. Testing for other antibodies is not recommended (American College of Obstetricians and Gynecologists, 2012b).

Antiphospholipid Antibody Syndrome Diagnosis

Clinical classification criteria shown in Table 59-5 provide indications for testing. By international consensus, the syndrome is diagnosed based on laboratory and clinical criteria (Miyakis, 2006). First, one of two clinical criteria—which are vascular thrombosis or certain pregnancy morbidity—must be present. In addition, at least one laboratory criterion that includes LAC activity or medium- to high-positive levels of specific IgG- or IgM-ACAs must be confirmed on two occasions 12 weeks apart.

Tests for LAC are nonspecific coagulation tests. The partial thromboplastin time is generally prolonged because the anticoagulant interferes with conversion of prothrombin to thrombin in vitro. Tests considered more specific are the dilute Russell viper venom test and the platelet neutralization procedure. There is currently disagreement as to which of these two is best for screening. If either is positive, then identification of LAC is confirmed.

Branch and Khamashta (2003) recommend conservative interpretation of results based on repeated tests from a reliable laboratory that are consistent with each clinical case. Only approximately 20 percent of patients with APS have a positive LAC reaction alone. Thus, anticardiolipin enzyme-linked immunosorbent assay (ELISA) testing should also be performed. Many laboratories have a premade panel to use for APS testing.

Efforts have been made to standardize ACA assays by using ELISA. Values are reported in units and expressed as negativelow-positive, medium-positive, or high-positive (Harris, 1987a,b). Despite this, these assays remain without international standardization (Adams, 2013; Branch, 2003; Capuano, 2007). Interlaboratory variation can be large, and agreement between commercial kits is poor.

Pregnancy and Antiphospholipid Antibodies

Nonspecific low levels of antiphospholipid antibodies are identified in approximately 5 percent of normal adults (Branch, 2010). When Lockwood and coworkers (1989) first studied 737 normal pregnant women, they reported that 0.3 percent had lupus anticoagulant and 2.2 percent had elevated concentrations of either IgM or IgG anticardiolipin antibodies. Later studies confirmed this, and taken together, they totaled almost 4000 normal pregnancies with an average prevalence for APAs of 4.7 percent. This is the same as for normal nonpregnant individuals (Harris, 1991; Pattison, 1993; Yasuda, 1995).

In women with high levels of ACAs, and especially when lupus anticoagulant is identified, there are increased risks for decidual vasculopathy, placental infarction, fetal-growth restriction, early-onset preeclampsia, and recurrent fetal death. Some of these women, like those with lupus, also have a high incidence of venous and arterial thromboses, cerebral thrombosis, hemolytic anemia, thrombocytopenia, and pulmonary hypertension (American College of Obstetricians and Gynecologists, 2012b; Clowse, 2008). In 191 LAC-negative women with antiphospholipid-antibody syndrome, women with antibodies to cardiolipin and β2-glycoprotein I had significantly higher miscarriage rates than if either one alone was positive (Liu, 2013).

Pregnancy Pathophysiology. It is not precisely known how these antibodies cause damage, but it is likely that their actions are multifactorial (Tsokos, 2011). Platelets may be damaged directly by antiphospholipid antibody or indirectly by binding β2-glycoprotein I, which causes platelets to be susceptible to aggregation (Chamley, 1999; Giannakopoulos, 2013). Rand and colleagues (1997a,b, 1998) propose that phospholipid-containing endothelial cell or syncytiotrophoblast membranes may be damaged directly by the antiphospholipid antibody or indirectly by antibody binding to either β2-glycoprotein I or annexin V. This prevents the cell membranes from protecting the syncytiotrophoblast and endothelium. It results in exposure of basement membrane to which damaged platelets can adhere and form a thrombus (Lubbe, 1984).

Pierro and associates (1999) reported that antiphospholipid antibodies decreased decidual production of the vasodilating prostaglandin E2. Decreased protein C or S activity and increased prothrombin activation may also be contributory (Ogunyemi, 2002; Zangari, 1997). Amengual and coworkers (2003) presented evidence that thrombosis with APS is due to activation of the tissue factor pathway. Finally, uncontrolled placental complement activation by antiphospholipid antibodies may play a role in fetal loss and growth restriction (Holers, 2002).

Complications from APS cannot be completely explained by thrombosis alone. Animal models suggest that these are due to inflammation rather than thrombosis (Cohen, 2011). Some investigators theorize that APS-associated clotting is triggered by a “second hit” from innate inflammatory immune responses and recommend antiinflammatory agents (Meroni, 2011).

Adverse Pregnancy Outcomes. Antiphospholipid antibodies are associated with increased rates of fetal wastage (Chap. 18p. 359). In most early reports, however, women were included because they had had repeated adverse outcomes. Both are common—recall that the incidence of antiphospholipid antibodies in the general obstetrical population is about 5 percent and early pregnancy loss approximates 20 percent. Accordingly, data currently are too limited to allow precise conclusions to be drawn concerning the impact of these antibodies on adverse pregnancy outcomes. Fetal deaths, however, are more characteristic with APS than are first-trimester miscarriages (Oshiro, 1996; Roque, 2001). It has also been shown that women with higher antibody titers have worse outcomes compared with those with low titers (Nodler, 2009; Simchen, 2009).

Looking at the issue another way, the frequency of antiphospholipid antibodies may be increased with associated adverse obstetrical outcomes. Polzin and colleagues (1991) identified antiphospholipid antibodies in a fourth of 37 women with growth-restricted fetuses, however, none had evidence for lupus anticoagulant. Approximately a third of women with APS will develop preeclampsia during pregnancy (Clark, 2007b). Moodley and associates (1995) found antiphospholipid antibodies in 11 percent of 34 women with severe preeclampsia before 30 weeks.

When otherwise unexplained fetal deaths are examined, the data are mixed. Haddow and coworkers (1991) measured ACAs in 309 pregnancies with fetal death and found no differences compared with those in 618 normal pregnancies. In women with a history of recurrent pregnancy loss, those with antiphospholipid antibodies had a higher rate of preterm delivery (Clark, 2007a). In a case-control study of 582 stillbirths and 1547 live births, Silver and colleagues (2013) found a three- to fivefold increased risk for stillbirth in women with elevated anticardiolipin and anti-β2-glycoprotein I levels. Due to the risk of fetal-growth abnormalities and stillbirth, serial sonographic assessment of fetal growth and antepartum testing in the third trimester are recommended by the American College of Obstetricians and Gynecologists (2012b).

Treatment in Pregnancy. Because of the heterogeneity of studies, current treatment recommendations for women with antiphospholipid antibodies can be confusing (Branch, 2003; Robertson, 2006). As discussed, antiphospholipid antibodies that bind to immunoglobulins G, M, and A are semiquantified, and GPL, MPL, and APL binding units are expressed as negative, low-positive, medium-positive, or high-positive (American College of Obstetricians and Gynecologists, 2012b). Of the three, higher titers for GPL and MPL anticardiolipin antibodies are clinically important, whereas low-positive titers are of questionable clinical significance. And any titer of APL antibodies has no known relevance at this time.

As discussed in Chapter 52 (p. 1033), women with prior thromboembolic events who have antiphospholipid antibodies are at risk for recurrence in subsequent pregnancies. For these women, prophylactic anticoagulation with heparin throughout pregnancy and for 6 weeks postpartum with either heparin or warfarin is recommended (American College of Obstetricians and Gynecologists, 2012b). For those without history of thromboembolic events, recommendations for management from the American College of Obstetricians and Gynecologists (2012b) and the American College of Chest Physicians (Bates, 2012) are varied and listed in Table 52-8 (p. 1046). Some acceptable schemes include close antepartum observation with or without prophylactic or intermediate-dose heparin, and some form of postpartum anticoagulation for 4 to 6 weeks.

Recent trials have caused the need for heparin to be questioned in women with antibodies but no history of thrombosis (Branch, 2010). Although this is less clear, some recommend that women be treated if they have medium- or high-positive ACA titers or LAC activity and a previous second- or third-trimester fetal death not attributable to other causes (Dizon-Townson, 1998; Lockshin, 1995). Some report that women with recurrent early pregnancy loss and medium- or high-positive titers of antibodies may benefit from therapy (Robertson, 2006). Some individual agents are now considered for pregnant women with antiphospholipid antibody syndrome who have no prior thromboembolic event. These agents are described in the following paragraphs.

Aspirin, given in doses of 60 to 80 mg orally daily, blocks the conversion of arachidonic acid to thromboxane A2 while sparing prostacyclin production. This reduces synthesis of thromboxane A2, which usually causes platelet aggregation and vasoconstriction, and simultaneously spares prostacyclin, which normally has the opposite effect. There appear to be no major side effects from low-dose aspirin other than a slight risk of small-vessel bleeding during surgical procedures. Low-dose aspirin does not appear to reduce adverse pregnancy outcomes in antiphospholipid antibody-positive women without the complete syndrome (Del Ross, 2013).

Unfractionated heparin is given subcutaneously in dosages of 5000 to 10,000 units every 12 hours. Some prefer low-molecular-weight heparin, such as 40 mg enoxaparin once daily, because of its ease of administration and smaller risk of osteoporosis and heparin-induced thrombocytopenia (Kwak-Kim, 2013). With therapeutic dosing, some recommend measurement of heparin levels because clotting tests may be altered by lupus anticoagulant (Cowchock, 1998). The rationale for heparin therapy is to prevent venous and arterial thrombotic episodes. Heparin therapy also prevents thrombosis in the microcirculation, including the decidual-trophoblastic interface (Toglia, 1996). As discussed, heparin binds to β2-glycoprotein I, which coats the syncytiotrophoblast. This prevents binding of anticardiolipin and anti-β2-glycoprotein I antibodies to their surfaces, which likely prevents cellular damage (Chamley, 1999; Tsokos, 2011). Heparin also binds to antiphospholipid antibodies in vitro and likely in vivo. It is problematic that heparin therapy is associated with a number of complications that include bleeding, thrombocytopenia, osteopenia, and osteoporosis. A detailed description of the use of various heparins and their doses and adverse effects is found in Chapter 52 (p. 1037).

Glucocorticosteroids generally should not be used with primary APS—that is, without an associated connective-tissue disorder. For women with lupus or those being treated for APS who develop lupus, corticosteroid therapy is indicated (Carbone, 1999). In such cases of secondary APS seen with lupus, the dose of prednisone should be maintained at the lowest effective level to prevent flares.

Immunoglobulin therapy is controversial and has usually been reserved for women with either overt disease or heparin-induced thrombocytopenia, or both (Alijotas-Reig, 2013). It is used when other first-line therapies have failed, especially in the setting of preeclampsia and fetal-growth restriction (Cowchock, 1996, 1998; Heilmann, 2003; Silver, 1997). Intravenous immunoglobulin (IVIG) is administered in doses of 0.4 g/kg daily for 5 days—total dose of 2 g/kg. This is repeated monthly, or it is given as a single dose of 1 g/kg each month. Treatment is expensive, and at $75 per gram, one course for a 70-kg woman costs more than $10,000. A Cochrane review of seven trials found no improvement in the livebirth rate for immunotherapy given to women with recurrent pregnancy loss (Porter, 2006). Xiao and associates (2013) studied prednisone and aspirin in 87 patients compared with prednisone, aspirin, low-molecular-weight heparin, and IVIG in 42 women with antiphospholipid antibody syndrome. They reported livebirth rates of 84 and 98 percent and obstetrical morbidity rates of 23 and 7 percent, respectively. We are of the view that randomized trials are needed before there is widespread application of this expensive and cumbersome therapy.

Immunosuppression has not been well evaluated, but azathioprine and cyclosporine do not appear to improve standard therapies (Silver, 1997). As mentioned with lupus on page 1172, methotrexate, cyclophosphamide, and mycophenolate mofetil are contraindicated because of teratogenic potential (Briggs, 2011; Buhimschi, 2009). Hydroxychloroquine therapy may be beneficial with APS (Albert, 2014).

Aspirin plus heparin is the most efficacious regimen (de Jesus, 2014). Low-dose unfractionated heparin—7500 to 10,000 units is used subcutaneously twice daily. Concurrently, low-dose aspirin—60 to 80 mg orally once daily—is given. Although typically given in addition to heparin in women with a prior thromboembolic event, the benefit of aspirin is unclear (American College of Obstetricians and Gynecologists, 2012b; Bouvier, 2014).

Treatment Efficacy. Fetal loss is common in women with antiphospholipid antibodies if untreated (Branch, 1992; Rai, 1995). Even with treatment, recurrent fetal loss rates remain at 20 to 30 percent (Branch, 2003; Empson, 2005; Ernest, 2011). Importantly, some women with lupus and antiphospholipid antibodies have normal pregnancy outcomes without treatment. Again, it is emphasized that women with lupus anticoagulant and prior bad pregnancy outcomes have had liveborns without treatment (Trudinger, 1988).

In a manner similar to neonatal lupus syndrome (p. 1172), up to 30 percent of neonates demonstrate passively acquired antiphospholipid antibodies, and thus there is concern for their adverse effects. For example, Tincani and coworkers (2009) found increased learning disabilities in these children. Simchen and colleagues (2009) reported a fourfold increased risk for perinatal strokes. Of 141 infants followed in a European registry, the rate of preterm birth was 16 percent; low birthweight, 17 percent; and behavioral abnormalities in 4 percent of the children. There were no cases of neonatal thrombosis (Motta, 2010).

image Rheumatoid Arthritis

This is a chronic multisystem disease of unknown cause with an immunologically mediated pathogenesis. Infiltrating T cells secrete cytokines that mediate inflammation and systemic symptoms. Its worldwide prevalence is 0.5 to 1 percent, women are affected three times more often than men, and peak onset is from 25 to 55 years (Shah, 2012). The cardinal feature is inflammatory synovitis that usually involves the peripheral joints. The disease has a propensity for cartilage destruction, bony erosions, and joint deformities. Criteria for classification are shown in Table 59-6, and a score of 6 or greater fulfills the requirements for definitive diagnosis.

TABLE 59-6. Criteria for Classification of Rheumatoid Arthritis

image

There is a genetic predisposition, and heritability is estimated at 15 to 30 percent (McInnes, 2011). Genome-wide associated studies have identified more than 30 loci involved in rheumatoid arthritis pathogenesis (Kurkó, 2013). There is an association with the class II major histocompatibility complex molecule HLA-DR4 and HLA-DRB1 alleles (McInnes, 2011; Shah, 2012). In addition, there is a genetic component to joint destruction in rheumatoid arthritis, as alterations in the IL2RA gene are associated with less destructive disease (Knevel, 2013). Cigarette smoking appears to increase the risk of rheumatoid arthritis (Papadopoulos, 2005). As discussed subsequently, a protective effect of pregnancy has been reported for development of rheumatoid arthritis, and this may be related to HLA-disparate fetal microchimerism (Guthrie, 2010; Hazes, 1990).

Clinical Manifestations

Rheumatoid arthritis is a chronic polyarthritis with symptoms of synovitis, fatigue, anorexia, weakness, weight loss, depression, and vague musculoskeletal symptoms. The hands, wrists, knees, and feet are commonly involved. Pain, aggravated by movement, is accompanied by swelling and tenderness. Extraarticular manifestations include rheumatoid nodules, vasculitis, and pleuropulmonary symptoms. The American College of Rheumatology criteria for rheumatoid arthritis diagnosis have been revised and are shown in Table 59-6 (Aletaha, 2010). The revision focuses on features at earlier stages to permit earlier therapy initiation with a goal of preventing or decreasing long-term sequelae.

Management

Treatment is directed at pain relief, inflammation reduction, protection of articular structures, and preservation of function. Physical and occupational therapy and self-management instructions are essential. Although aspirin and other NSAIDs are the cornerstone of symptomatic therapy, they do not retard disease progression. Conventional NSAIDs nonspecifically inhibit both cyclooxygenase-1 (COX-1)—an enzyme critical to normal platelet function, and COX-2—an enzyme that mediates inflammatory response mechanisms. Gastritis with acute bleeding is an unwanted side effect common to conventional NSAIDs. Specific COX-2 inhibitors have been used to avert this complication. However, there are now concerns that their long-term use is associated with increased risk for myocardial infarction, stroke, and heart failure (Solomon, 2005). A systematic review by Adams and colleagues (2012) identified two studies of women treated for inflammatory arthritis. They reported a higher rate of cardiac malformations in infants exposed to NSAIDs in the first trimester. In addition, NSAIDs are associated with early spontaneous abortions, ductus constriction, and neonatal pulmonary hypertension (Briggs, 2011). Thus, risks versus benefits of these medications must be considered.

Glucocorticoid therapy may be added to NSAIDs. Of these, prednisone, 7.5 mg orally daily for the first 2 years of active disease, substantively reduces progressive joint erosions (Kirwan, 1995). Although corticosteroids are usually avoided if possible, low-dose therapy is used by some along with salicylates.

Because NSAIDs and glucocorticoids are primarily for symptomatic relief, the American College of Rheumatology (2012) recommends disease-modifying antirheumatic drugs (DMARDs). These have the potential to reduce or prevent joint damage and are given within 3 months of diagnosis. There are several DMARDs, and many have considerable toxicity. For example, methotrexate and leflunomide are teratogenic (Briggs, 2011). Sulfasalazine and hydroxychloroquine are safe for use in pregnancy (Partlett, 2011; Raza, 2010). These, combined with COX-2 inhibitors and with relatively low-dose prednisone—7.5 to 20 mg daily—for flares are often all the pharmacotherapy needed. Azathioprine treatment may be used if immunosuppressive drugs are warranted. From their review, Kuriya and associates (2011) found that a fourth of women with rheumatoid arthritis took a DMARD within 6 months of conception. During pregnancy, 4 percent of 393 pregnant women were given a category D or X medication. Methotrexate was the most common—2.9 percent. These authors advocate continued efforts to counsel women and their physicians regarding potential risks of many rheumatoid arthritis therapies during pregnancy.

Cytokine inhibitors, which include etanercept (Enbrel), adalimumab (Humira), and infliximab (Remicade), are also being used (McInnes, 2011). The newer immune-targeted drugs for rheumatoid arthritis have shown great promise. But, their use in pregnancy is limited, and fetal safety issues are a concern (Makol, 2011; Ojeda-Uribe, 2013). In the review by Kuriya and coworkers (2011) discussed earlier, 13 percent of 393 women were given a biological cytokine-inhibiting DMARD—primarily etanercept. Experience with these agents in pregnancy has been accruing (Verstappen, 2011). Berthelot and colleagues (2009) found more than 300 reported cases in their review and noted no fetal effects from exposure. Patients considered for etanercept treatment can be entered into a registry at 877-311-8972. There is also little known regarding pregnancy effects of the interleukin-1 receptor antagonist, anakinra (Kineret), and the antagonist to the B-cell CD20 antigen, rituximab (Rituxan).

Other drugs used less frequently include penicillamine, gold salts, minocycline, and cyclosporine. Orthopedic surgery for joint deformities, including replacement, is frequently performed outside of pregnancy.

Pregnancy and Rheumatoid Arthritis

Up to 90 percent of women with rheumatoid arthritis will experience improvement during pregnancy (de Man, 2008). Animal studies suggest this may be due to regulatory T-cell alterations. Transfer of regulatory T cells from pregnant mice conferred protection to those not pregnant (Munoz-Suano, 2012). That said, some women develop disease during pregnancy, and others become worse (Nelson, 1997).

A downside to this respite during pregnancy is that postpartum exacerbation is common (Østensen, 2007). This may be due to alterations in innate immunity postpartum (Häupl, 2008b). Barrett and coworkers (2000a) reported that a postpartum flare was more common if women were breast feeding. These same investigators performed a prospective United Kingdom study involving 140 women with rheumatoid arthritis (Barrett, 2000b). During 1 to 6 months postpartum, there was only a modest fall in objective disease activity, and only 16 percent had complete remission. At least 25 percent had substantive levels of disability. They observed that although overall disease actually did not exacerbate postpartum, the mean number of inflamed joints increased significantly.

There are some studies that report a protective effect of pregnancy for women developing subsequent new-onset rheumatoid arthritis. Silman and associates (1992) performed a case-control study of 88 affected women. They found that although there was a protective effect of pregnancy in the long term, the likelihood of new-onset rheumatoid arthritis was increased sixfold during the first 3 postpartum months. Pikwer and colleagues (2009) reported a significant reduction in the risk of subsequent arthritis in women who breast fed longer than 12 months.

As an explanation for these findings, and as discussed previously, sex hormones supposedly interfere with a number of putative processes involved in arthritis pathogenesis, including immunoregulation and interactions with the cytokine system (Häupl, 2008a,b). First, Unger and associates (1983) reported that amelioration of rheumatoid arthritis correlated with serum levels of pregnancy-associated α2-glycoprotein. This compound has immunosuppressive properties. Second, Nelson and coworkers (1993) reported that amelioration of disease was associated with a disparity in HLA class II antigens between mother and fetus. They suggested that the maternal immune response to paternal HLA antigens may play a role in pregnancy-induced remission of arthritis. In addition to monocyte activations, there also may be T-lymphocyte activation (Förger, 2008).

Juvenile Rheumatoid Arthritis

This is a group of diseases that are the most frequent cause of chronic arthritis in children. They persist into adulthood. Østensen (1991) reviewed outcomes of 76 pregnancies in 51 affected Norwegian women. Pregnancy had no effects on presentation of disease, but disease activity usually became quiescent or remained so during pregnancy. Postpartum flares were common as was discussed for rheumatoid arthritis. Joint deformities often developed in these women, and 15 of 20 cesarean deliveries were done for contracted pelves or joint prostheses. These observations are supported by the summary of similar results in 39 Polish women with juvenile rheumatoid arthritis (Musiej-Nowakowska, 1999).

Perinatal Outcome. There are no obvious adverse effects of rheumatoid arthritis on pregnancy outcome, but an increased risk for preterm birth is debated (Klipple, 1989; Langen, 2014; Wallenius, 2011). In a population-based cohort study, Skomsvoll and associates (2002) reported that women with rheumatic disease with two previous poor pregnancy outcomes were at high risk for recurrent adverse outcomes. Kaplan (1986) reported that women who later develop the disease had a prior higher-than-expected incidence of spontaneous abortion. However, Nelson and colleagues (1992) did not corroborate this.

Management During Pregnancy. Treatment of symptomatic women during pregnancy is with aspirin and NSAIDs. These are used with appropriate concerns for first-trimester effects, impaired hemostasis, prolonged gestation, premature ductus arteriosus closure, and persistent pulmonary circulation (Chap. 12p. 247) (Briggs, 2011). Low-dose corticosteroids are also prescribed as indicated. Gold compounds have been administered in pregnancy. Of 14 women experiencing 20 pregnancies on gold therapy, 75 percent delivered healthy liveborn neonates (Almarzouqi, 2007).

Immunosuppressive therapy with azathioprine, cyclophosphamide, or methotrexate is not routinely used during pregnancy. Of these, only azathioprine should be considered during early pregnancy because the other agents are teratogenic (Briggs, 2011; Buhimschi, 2009). As noted earlier, DMARDs including sulfasalazine and hydroxychloroquine are acceptable for use in pregnancy.

If the cervical spine is involved, particular attention is warranted during pregnancy. Subluxation is common, and pregnancy, at least theoretically, predisposes to this because of joint laxity (Chap. 4p. 71). Importantly, there are anesthesia concerns regarding endotracheal intubation.

Following pregnancy, contraceptive counseling may include combination oral contraceptives. These are a logical choice because of their effectiveness and their potential to improve disease (Bijlsma, 1992; Farr, 2010). That said, all methods of contraception are appropriate.

image Systemic Sclerosis—Scleroderma

This is a chronic multisystem disorder of unknown etiology. It is characterized by microvascular damage, immune system activation leading to inflammation, and excessive deposition of collagen in the skin and often in the lungs, heart, gastrointestinal tract, and kidneys. It is uncommon, displays a 3-to-1 female dominance, and typically affects those aged 30 to 50 years.

This strong prevalence of scleroderma in women and its increased incidence in the years following childbirth contribute to the hypothesis that microchimerism is involved as discussed on page 1168 (Lambert, 2010). Artlett and coworkers (1998) demonstrated Y-chromosomal DNA in almost half of women with systemic sclerosis compared with only 4 percent of controls. Rak and colleagues (2009b) identified male microchimerism in peripheral blood mononuclear cells more frequently in women with limited versus diffuse scleroderma—20 versus 5 percent.

Clinical Course

The hallmark is overproduction of normal collagen. In the more benign form—limited cutaneous systemic sclerosis—progression is slow. With diffuse cutaneous systemic sclerosis, skin thickening progresses rapidly, and skin fibrosis is followed by gastrointestinal tract fibrosis, especially the distal esophagus (Varga, 2012). Pulmonary interstitial fibrosis along with vascular changes may cause pulmonary hypertension. Antinuclear antibodies are found in 95 percent of patients, and immunoincompetence often develops.

Frequent symptoms are Raynaud phenomenon, which includes cold-induced episodic digital ischemia in 95 percent, as well as swelling of the distal extremities and face. Half of patients have symptoms from esophageal involvement, especially fullness and epigastric burning pain. Pulmonary involvement is common and causes dyspnea. The 10-year cumulative survival rate is 70 percent in those with pulmonary fibrosis, and pulmonary arterial hypertension is the main causes of death (Joven, 2010; Ranque, 2010). Women with limited cutaneous disease such as the CREST syndrome—calcinosis, Raynaud phenomenon, esophageal involvement, sclerodactyly, and telangiectasia—have milder disease.

Overlap syndrome refers to the presence of systemic sclerosis with features of other connective-tissue disorders. Mixed-connective-tissue disease is a term used for the syndrome involving features of lupus, systemic sclerosis, polymyositis, rheumatoid arthritis, and high titers of anti-RNP antibodies (see Table 59-1). The disorder is also termed undifferentiated connective-tissue disease (Spinillo, 2008).

Although systemic sclerosis cannot be cured, treatment directed at end-organ involvement can relieve symptoms and improve function (Varga, 2012). Hydroxychloroquine and low-dose corticosteroids are helpful, and intravenous immunoglobulin may be indicated for pericarditis and hemolytic anemia. Renal involvement and hypertension are common. At times, angiotensin-converting enzyme (ACE) inhibitors may be required for blood pressure control despite their known teratogenicity (Buhimschi, 2009). Scleroderma renal crisis develops in up to a fourth of these patients and is characterized by obliterative vasculopathy of the renal cortical arteries. This results in renal failure and malignant hypertension. Interstitial restrictive lung disease is common and frequently becomes life threatening. Associated pulmonary hypertension is usually fatal. Cyclophosphamide provides some improvement (Tashkin, 2006).

Pregnancy and Systemic Sclerosis

The prevalence of scleroderma in pregnancy is estimated from a study of nearly 11.2 million pregnant women registered in the Nationwide Inpatient Sample. In this study, Chakravarty and associates (2008) reported that 504 women suffered from systemic sclerosis—a prevalence of approximately 1 in 22,000 pregnancies. These women usually have stable disease during gestation if their baseline function is good. As perhaps expected, dysphagia and reflux esophagitis are aggravated by pregnancy (Steen, 1999). Dysphagia results from loss of esophageal motility due to neuromuscular dysfunction. A decrease in amplitude or disappearance of peristaltic waves in the lower two thirds of the esophagus is seen using manometry. Symptomatic treatment for reflux is described in Chapter 54 (p. 1072). Women with renal insufficiency and malignant hypertension have an increased incidence of superimposed preeclampsia. In the presence of rapidly worsening renal or cardiac disease, pregnancy termination should be considered. As discussed, renal crisis is life threatening and is treated with ACE inhibitors, but it does not improve with delivery (Gayed, 2007). Pulmonary hypertension usually contraindicates pregnancy (Chap. 49p. 987).

Vaginal delivery may be anticipated, unless the soft tissue thickening wrought by scleroderma produces dystocia requiring cesarean delivery. Tracheal intubation for general anesthesia has special concerns because of limited ability of these women to open their mouths widely (Black, 1989). Because of esophageal dysfunction, aspiration is also more likely, and epidural analgesia is preferable.

Pregnancy Outcomes

Maternal and fetal outcomes are related to the severity of underlying disease. Steen and colleagues (1989, 1999) described pregnancies in 214 women with systemic sclerosis—45 percent had diffuse disease. Major complications included renal crisis in three women and increased rates of preterm birth. Chung and coworkers (2006) also reported increased rates of preterm delivery, fetal-growth restriction, and perinatal mortality. A multicenter study of 109 pregnancies from 25 centers reported higher rates of preterm delivery, fetal-growth restriction, and very-low-birthweight infants (Taraboreli, 2012). These are likely related to placental abnormalities that include decidual vasculopathy, acute atherosis, and infarcts. These reduce placental blood flow and are found in many cases (Doss, 1998; Papakonstantinou, 2007).

Contraception

Scleroderma may be associated with subfertility (Bernatsky, 2008; Lambe, 2004). For women who do not choose pregnancy, several reversible contraceptive methods are acceptable. However, hormonal agents, especially combination oral contraceptives, probably should not be used, especially in women with pulmonary, cardiac, or renal involvement. Due to the often unrelenting progression of systemic sclerosis, permanent sterilization should also be considered.

image Vasculitis Syndromes

Inflammation and damage to blood vessels may be primary or due to another disease. Most cases are presumed to be caused by immune-complex deposition (Langford, 2012). Primary causes include polyarteritis nodosa, Wegener granulomatosis, Churg-Strauss syndrome, temporal or giant cell arteritis, Takayasu arteritis, Henoch-Schönlein purpura, Behçet syndrome, and cutaneous or hypersensitivity arteritis (Goodman, 2014). Some of these syndromes have antibodies directed against proteins in the cytoplasmic granules of leukocytes—antineutrophil cytoplasmic antibodies—ANCA. Their role in vasculitis is unclear, and disease activity is not related to increasing titers.

Polyarteritis Nodosa

This necrotizing vasculitis of small and medium-sized arteries is characterized clinically by myalgia, neuropathy, gastrointestinal disorders, hypertension, and renal disease (Goodman, 2014). Approximately a third of cases are associated with hepatitis B antigenemia (Langford, 2012).

Symptoms are nonspecific and vague. Fever, weight loss, and malaise are present in more than half of cases. Renal failure, hypertension, and arthralgias are common. Diagnosis is made by biopsy, and treatment consists of high-dose prednisone plus cyclophosphamide. Vasculitis due to hepatitis B antigenemia responds to antivirals, glucocorticoids, and plasma exchange (Chap. 55p. 1090).

There have been only a few reports of documented cases of polyarteritis nodosa associated with pregnancy. Even without definitive data, active arteritis in pregnancy is associated with high mortality rates. Owen and Hauth (1989) reviewed the courses of 12 such pregnant women. In seven, polyarteritis first manifested during pregnancy, and it was rapidly fatal by 6 weeks postpartum. The diagnosis was not made until autopsy in six of the seven women. Four women continued pregnancy, which resulted in one stillborn and three successful outcomes.

Wegener Granulomatosis

This is a necrotizing granulomatous vasculitis of the upper and lower respiratory tract and kidney. Disease frequently includes sinusitis and nasal disease—90 percent; pulmonary infiltrates, cavities, or nodules—85 percent; glomerulonephritis—75 percent; and musculoskeletal lesions—65 percent (Sneller, 1995). At least 90 percent have polyangiitis (Langford, 2012). It is uncommon and usually encountered after 50 years of age. Koukoura and associates (2008) reviewed 36 cases reported in association with pregnancy. In another report, a woman with Wegener disease developed thrombotic microangiopathy associated renal impairment at 32 weeks. A second woman had pneumonitis, but pregnancy did not appear to affect disease activity (Pagnoux, 2011). Because subglottic stenosis is found in up to a fourth, the anesthesia team should be consulted during pregnancy (Engel, 2011; Kayatas, 2012).

Corticosteroids are standard treatment, but azathioprine, cyclosporine, and intravenous immunoglobulin may also be used. For severe disease in the late second or third trimester, cyclophosphamide in combination with prednisolone seems acceptable.

Takayasu Arteritis

Also called pulseless disease, this syndrome is most prevalent in young women. It is a chronic inflammatory arteritis affecting large vessels (Goodman, 2014). Unlike temporal arteritis, which develops almost exclusively after age 55, the onset of Takayasu arteritis is almost always before age 40. It is associated with abnormal angiography of the upper aorta and its main branches and with upper extremity vascular impairment. Death usually results from congestive heart failure or cerebrovascular events. Computed tomography or magnetic resonance angiography can detect this disorder before the development of severe vascular compromise (Numano, 1999). Takayasu arteritis may respond symptomatically to corticosteroid therapy, however, it is not curative. Selection of surgical bypass or angioplasty has improved survival rates.

Severe renovascular hypertension, cardiac involvement, or pulmonary hypertension worsen pregnancy prognosis. Hypertension is relatively common and should be carefully controlled. Blood pressure is measured in the lower extremity. Overall, the prognosis for pregnancy is good (de Jesús, 2012; Hernández-Pacheco, 2011; Hidaka, 2012; Johnston, 2002; Kraemer, 2008; Mandal, 2012). When the abdominal aorta is involved, however, pregnancy outcome may be disastrous (Sharma, 2000). Vaginal delivery is preferred, and epidural analgesia has been advocated for labor and delivery (Langford, 2002).

Other Vasculitides

Vasculitis caused by Henoch-Schönlein purpura is uncommon after childhood. Tayabali and associates (2012) reviewed 20 pregnancies complicated by this vasculitis and described cutaneous lesions in three fourths. Approximately half had arthralgias. Jadaon and colleagues (2005) described 135 pregnancies in 31 women with Behçet disease compared with matched nonaffected controls. Although there were no deleterious effects of pregnancy on the underlying disease, the miscarriage rate was significantly increased threefold. Hwang and coworkers (2009) described necrotizing villitis and decidual vasculitis in a placenta from a first-trimester pregnancy termination and another from a term delivery. Churg-Strauss vasculitis is rare in pregnancy. Hot and associates (2007) described a pregnant woman who responded to intravenous immune globulin therapy. Corradi and associates (2009) described an affected 35-year-old woman at term whose necrotizing vasculitis involved the heart, and she subsequently underwent cardiac transplantation.

INFLAMMATORY MYOPATHIES

This is the largest group of acquired and potentially treatable causes of skeletal muscle weakness. That said, these disorders have a prevalence of 1 in 100,000 persons (Dalakas, 2012). There are three major groups: polymyositis, dermatomyositis, and inclusion-body myositis, which all present with progressive asymmetrical muscle weakness. They have a variable association with connective-tissue diseases, malignancy, drugs, systemic autoimmune disease such as Crohn disease, and viral, bacterial, and parasitic infections.

Polymyositis is a subacute inflammatory myopathy that is frequently associated with one of the autoimmune connective-tissue disorders. Dermatomyositis manifests as a characteristic rash accompanying or preceding weakness. Laboratory findings include elevated muscle enzyme levels in serum and an abnormal electromyogram. Confirmation is by biopsy, which shows perivascular and perimysial inflammatory infiltrates, vasculitis, and muscle fiber degeneration. It usually develops alone but can overlap with scleroderma or mixed connective-tissue disease.

Prevailing theories suggest that the syndromes are caused by viral infections, autoimmune disorders, or both. Importantly, approximately 15 percent of adults who develop dermatomyositis have an associated malignant tumor. The timing of myositis and tumor appearance may be separated by several years. The most common sites of associated cancer are breast, lung, stomach, and ovary. The disease usually responds to high-dose corticosteroid therapy, immunosuppressive drugs such as azathioprine or methotrexate, or IVIG (Dalakas, 2012; Williams, 2007). Linardaki and colleagues (2011) report successful treatment with IVIG and corticosteroids in pregnancy.

Experiences in pregnancy are garnered mostly from case series and reviews. Gutierrez and coworkers (1984) reviewed outcomes in 10 pregnancies among seven women with active disease. They reported three abortions, three perinatal deaths, and five preterm deliveries. Rosenzweig and colleagues (1989) reviewed 24 pregnancy outcomes in 18 women with primary polymyositis-dermatomyositis. In 12, the diagnosis preceded pregnancy. Of these, a fourth had an exacerbation in the second or third trimester. Excluding abortions, there were two perinatal deaths and two growth-restricted neonates. In the other 12 in whom disease became manifest first during pregnancy, outcomes were even less favorable. Excluding abortions, half of the eight pregnancies resulted in perinatal death, and one woman died postpartum. Ohno (1992) and Papapetropoulos (1998) and their coworkers described similar cases. From their review, Doria and associates (2004) concluded that pregnancy outcome was related to disease activity and that new-onset disease was particularly aggressive.

HEREDITARY CONNECTIVE-TISSUE DISORDERS

Numerous inherited mutations involve genes that encode for structural proteins of bone, skin, cartilage, blood vessels, and basement membranes. Although connective tissues contain many complex macromolecules such as elastin and more than 30 proteoglycans, the most common constituents are fibrillar collagen types I, II, and III. Various mutations, some recessively and some dominantly inherited, result in clinical syndromes that include Marfan and Ehlers-Danlos syndromes, osteogenesis imperfecta, chondrodysplasias, and epidermolysis bulla. Of concern during pregnancy is the predilection for these disorders to result in aortic aneurysms (Schoenhoff, 2013).

image Marfan Syndrome

This is a common autosomal dominant connective-tissue disorder that has a prevalence of 1 in 3000 to 5000 (Prockop, 2012). Marfan syndrome affects both sexes equally. It is caused by a mutation of the fibrillin-1 (FBN1) gene on the long arm of chromosome 15 (Loeys, 2002). The FBN1 gene has a high mutation rate, and there are many mild, subclinical cases. In severe disease, there is degeneration of the elastic lamina in the media of the aorta. This weakness predisposes to aortic dilatation or dissecting aneurysm, which appears more commonly during pregnancy (Bloom, 2010; Curry, 2014; Savi, 2007). Marfan syndrome complicating pregnancy is discussed in detail in Chapter 49 (p. 993).

image Ehlers–Danlos Syndrome

This disease is characterized by various connective tissue changes, including skin hyperelasticity. In the more severe types, there is a strong tendency for rupture of any of several arteries to cause either stroke or bleeding. Rupture of the colon or uterus has been described. There are several types of disease based on skin, joint, or other tissue involvement. Some are autosomal dominant, some recessive, and some X-linked (Solomons, 2013). Their aggregate prevalence is approximately 1 in 5000 births (Prockop, 2012). Types I, II, and III are autosomally dominant, and each accounts for about 30 percent of cases. Type IV is uncommon but is known to predispose to preterm delivery, maternal great-vessel rupture, postpartum bleeding, and uterine rupture (Pepin, 2000). In most, the underlying molecular defect is one of collagen or procollagen.

In general, women with Ehlers-Danlos syndrome have an increased frequency of preterm rupture of membranes, preterm delivery, and antepartum and postpartum hemorrhage (Volkov, 2006). Several cases of spontaneous uterine rupture have been described (Bloom, 2010; Rudd, 1983; Walsh, 2007). Tissue fragility makes episiotomy repair and cesarean delivery difficult. Sorokin and colleagues (1994) surveyed female members of the Ehlers-Danlos National Foundation. They reported a stillbirth rate of 3 percent, a preterm delivery rate of 23 percent, and a cesarean delivery rate of 8 percent. Fifteen percent had problematic postpartum bleeding. A maternal and fetal death from spontaneous rupture of the right iliac artery was described by Esaka and coworkers (2009). Finally, Bar-Yosef and associates (2008) described a newborn with multiple congenital skull fractures and intracranial hemorrhage caused by Ehlers-Danlos type VIIC.

image Osteogenesis Imperfecta

This disorder is characterized by very low bone mass resulting in brittle bones. Affected patients often have blue sclerae, hearing loss, a history of multiple fractures, and dental abnormalities. There are seven subtypes that range from severe to mild clinical disease. Subtypes show differing genetic inheritance and include autosomal dominant, autosomal recessive, and sporadic patterns. Type I is the mildest form, whereas type II is typically lethal in utero (Prockop, 2012). There are well-characterized gene mutations coding for type I procollagen. These are associated with the specific subtypes. For example, the typical mutation with type I is a premature stop codon in the COL1A1 gene (Sykes, 1990). Osteogenesis imperfecta has a prevalence of 1 in 30,000 births for type I and 1 in 60,000 for type II.

Women with osteogenesis imperfecta, most commonly type I, may have successful pregnancies (Lyra, 2010). That said, there are several risks in pregnancy, including fractures, complications related to scoliosis with restrictive lung disease, micrognathia, brittle teeth, an unstable cervical spine, uterine rupture, and cephalopelvic disproportion. These women may also have hyperthyroidism and valvular heart disease. It is not unusual for affected women to enter pregnancy having had 20 to 30 prior fractures. Most women with this skeletal disorder require minimal treatment other than management of the fractures and consideration of bisphosphonates to decrease bone loss. The anesthesia team should be consulted during pregnancy regarding plans for delivery (Murray, 2010).

Depending on the type of osteogenesis imperfecta, the fetus may be affected and may also suffer fractures in utero or during delivery (Chap. 10p. 217). Prenatal diagnosis is available in many situations, if desired.

REFERENCES

Adams K, Bombardier C, van der Heijde DM: Safety of pain therapy during pregnancy and lactation in patients with inflammatory arthritis: a systematic literature review. J Rheumatol Suppl 90:59, 2012

Adams KM, Nelson JL: Microchimerism: An investigative frontier in autoimmunity and transplantation. JAMA 291:1127, 2004

Adams M: Measurement of lupus anticoagulants: an update on quality in laboratory testing. Semin Thromb Hemost 39(3):267, 2013

Aggarwal N, Sawhney H, Vasishta K, et al: Pregnancy in patients with systemic lupus erythematosus. Aust N Z J Obstet Gynaecol 39:28, 1999

Aggarwal R, Sestak AL, Chakravarty EF, et al: Excess female siblings and male fetal loss in families with systemic lupus erythematosus. J Rheumatol 40(4):430, 2013

Ahmed K, Darakhshan A, Au E, et al: Postpartum spontaneous colonic perforation due to antiphospholipid syndrome. World J Gastroenterol 15(4):502, 2009

Albert CR, Schlesinger WJ, Viall CA, et al: Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol 71:154, 2014

Aletaha D, Neogi T, Silman AJ, et al: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580, 2010

Alijotas-Reig J: Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22(1):6, 2013

Almarzouqi M, Scarsbrook D, Klinkhoff A: Gold therapy in women planning pregnancy: outcomes in one center. J Rheumatol 34:1827, 2007

Amengual O, Atsumi T, Khamashta MA: Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium. Rheumatology 42:1029, 2003

American College of Obstetricians and Gynecologists: Antepartum fetal surveillance. Practice Bulletin No. 9, October 1999, Reaffirmed 2012a

American College of Obstetricians and Gynecologists: Antiphospholipid syndrome. Practice Bulletin No. 132, December 2012b

American College of Obstetricians and Gynecologists: Use of hormonal contraception in women with coexisting medical conditions. Practice Bulletin No. 73, June 2006, Reaffirmed 2013

American College of Rheumatology: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46(2):328, 2002

Anderka MT, Lin AE, Abuelo DN: Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 149A(6):1241, 2009

Arbuckle MF, McClain MT, Rubertone MV, et al: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526, 2003

Artlett CM, Smith B, Jimenez SA: Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338:1186, 1998

Avalos I, Tsokos GC: The role of complement in the antiphospholipid syndrome-associated pathology. Clin Rev Allergy Immunol 34(2–3):141, 2009

Barrett JH, Brennan P, Fiddler M, et al: Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum 43:1010, 2000a

Barrett JH, Brennan P, Fiddler M, et al: Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 42:1219, 2000b

Bar-Yosef O, Polak-Charcon S, Hoffman C, et al: Multiple congenital skull fractures as a presentation of Ehlers-Danlos syndrome type VIIC. Am J Med Genet A 146A:3054, 2008

Bates SM, Greer IA, Middledorp S, et al: VTE, thrombophilia, antithrombotic therapy, and pregnancy. Chest 141(2 Suppl):e691S, 2012

Bernatsky S, Hudson M, Pope J, et al: Assessment of reproductive history in systemic sclerosis. Arthritis Rheum 59:1661, 2008

Berthelot JM, De Bandt M, Goupille P, et al: Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76(1):28, 2009

Bertsias G, Ionnidis JPA, Boletis J, et al: EULAR recommendations for the management of systemic lupus erythematosus (SLE). Ann Rheum Dis 67(2):195, 2008

Bijlsma JWJ, Van Den Brink HR: Estrogens and rheumatoid arthritis. Am J Reprod Immunol 28:231, 1992

Binder WD, Traum AZ, Makar RS, et al: Case 37-2010: a 16-year-old girl with confusion, anemia, and thrombocytopenia. N Engl J Med 363(24):2352, 2010

Black CM, Stevens WM: Scleroderma. Rheum Dis Clin North Am 15:193, 1989

Bloom SL, Uppot R, Roberts DJ: Case records of the Massachusetts General Hospital. Case 32-2010. A pregnant woman with abdominal pain and fluid in the peritoneal cavity. N Engl J Med 363(17):1657, 2010

Boh EE: Neonatal lupus erythematosus. Clin Dermatol 22:125, 2004

Borden M, Parke A: Antimalarial drugs in systemic lupus erythematosus. Drug Saf 24:1055, 2001

Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al: Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 123:404, 2014

Bramham K, Soh MC, Nelson-Piercy C: Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus 21(12):1271, 2012

Branch DW, Gibson M, Silver RM: Recurrent miscarriage. N Engl J Med 363:18, 2010

Branch DW, Khamashta M: Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 101:1333, 2003

Branch DW, Silver RM, Blackwell JL, et al: Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 80:614, 1992

Briggs GG, Freeman RK, Sumner J, et al (eds): Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk. 9th ed. Philadelphia, Lippincott Williams & Wilkins, 2011

Buhimschi CS, Weiner CP: Medications in pregnancy and lactation. Part 1. Teratol Obstet Gynecol 113:166, 2009

Buyon J, Kalunian K, Ramsey-Goldman R, et al: Assessing disease activity in SLE patients during pregnancy. Lupus 8:677, 1999

Buyon JP, Winchester RJ, Slade SG, et al: Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunoabsorbent assay and immunoblot for measurement of anti SSA/Ro and anti SSB/La antibodies. Arthritis Rheum 36:1263, 1993

Capuano F, Grasso V, Belforte L, et al: Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues. Ann N Y Acad Sci 1109:493, 2007

Carbone J, Orera M, Rodriguez-Mahou M, et al: Immunological abnormalities in primary APS evolving into SLE: 6 years’ follow-up in women with repeated pregnancy loss. Lupus 8:274, 1999

Chabbert-Buffet N, Amoura Z, Scarabin PY, et al: Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception 83(3):229, 2011

Chakravarty EF, Khanna D, Chung L: Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. Obstet Gynecol 111(4):927, 2008

Chamley LW, Duncalf AM, Konarkowska B, et al: Conformationally altered beta(2)-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Clin Exp Immunol 115:571, 1999

Chung L, Flyckt RL, Colon I, et al: Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. Lupus 15:595, 2006

Clark CA, Spitzer KA, Crowther MA, et al: Incidence of postpartum thrombosis and preterm delivery in women with antiphospholipid antibodies and recurrent pregnancy loss. J Rheumatol 34:992, 2007a

Clark EAS, Silver RM, Branch DW: Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheum Rep 9:219, 2007b

Clowse ME, Jamison M, Myers E, et al: A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 199:127.e1, 2008

Cohen D, Buurma A, Goemaere NN, et al: Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol 225(4):502, 2011

Contreras G, Pardo V, Leclercq B, et al: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971, 2004

Corradi D, Maestri R, Facchetti F: Postpartum Churg-Strauss syndrome with severe cardiac involvement: description of a case and review of the literature. Clin Rheumatol 28(6):739, 2009

Cowchock S: Prevention of fetal death in the antiphospholipid antibody syndrome. Lupus 5:467, 1996

Cowchock S: Treatment of antiphospholipid syndrome in pregnancy. Lupus 7:S95, 1998

Curry R, Gelson E, Swan L, et al: Marfan syndrome and pregnancy: maternal and neonatal outcomes. BJOG January 13, 2014 [Epub ahead of print]

Cutolo M, Capellino S, Sulli A, et al: Estrogens and autoimmune diseases. Ann N Y Acad Sci 1089:538, 2006

Dalakas MC: Polymyositis, dermatomyositis, and inclusion body myositis. In Longo DL, Fauci AS, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012, p 3508

D’Cruz D: Renal manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 11(1):52, 2009

de Man YA, Dolhain RJ, van de Geijn FE, et al: Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 59:1241, 2008

de Jesús GR, d’Oliveira IC, dos Santos FC, et al: Pregnancy may aggravate arterial hypertension in women with Takayasu arteritis. Isr Med Assoc J 14(12):724, 2012

de Jesus GR, Rodrigues G, de Jesus NR, et al: Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep 16:403, 2014

Del Ross T, Ruffatti A, Wisentin MS, et al: Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. J Rheumatol 40(4):425, 2013

Diamond B, Bloom O, Al Abed Y, et al: Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus. J Intern Med 269(1):36, 2011

Dizon-Townson D, Branch DW: Anticoagulant treatment during pregnancy: an update. Semin Thromb Hemost 24:55S, 1998

Doria A, Iaccarino L, Ghirardello A, et al: Pregnancy in rare autoimmune rheumatic diseases: UCTD, MCTD, myositis, systemic vasculitis and Behçet disease. Lupus 13:690, 2004

Doss BJ, Jacques SM, Mayes MD, et al: Maternal scleroderma: placental findings and perinatal outcome. Hum Pathol 29(12):1524, 1998

Egerman RS, Ramsey RD, Kao LW, et al: Hypertensive disease in pregnancies complicated by systemic lupus erythematosus. Am J Obstet Gynecol 193:1676, 2005

Empson M, Lassere M, Craig J, et al: Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2:CD002859, 2005

Engel NM, Gramke HF, Peeters L, et al: Combined spinal-epidural anaesthesia for a woman with Wegener’s granulomatosis with subglottic stenosis. Int J Obstet Anesth 20(1):94, 2011

Erkan D, Derksen R, Levy R, et al: Antiphospholipid Syndrome Clinical Research Task Force report. Lupus 20(2):219, 2011

Ernest JM, Marshburn PB, Kutteh WH: Obstetric antiphospholipid syndrome: an update on pathophysiology and management. Semin Reprod Med 29:522, 2011

Esaka EJ, Golde SH, Stever MR, et al: A maternal and perinatal mortality in pregnancy complicated by the kyphoscoliotic form of Ehlers-Danlos syndrome. Obstet Gynecol 113(2):515, 2009

Farr SL, Folger SG, Paulen ME, et al: Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review. Contraception 82(1):64, 2010

Feinstein DI, Rapaport SI: Acquired inhibitors of blood coagulation. In Spaet TH (ed): Progress in Hemostasis and Thrombosis, Vol 1. New York, Grune & Stratton, 1972, p 75

Fischer-Betz R, Specker C, Brinks R, et al: Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 52(6):1070, 2013

Food and Drug Administration: FDA Alert: inosine monophosphate dehydrogenase inhibitors (IMPDH) immunosuppressants. May 16, 2008. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124776.htm. Accessed June 15, 2013

Förger F, Marcoli N, Gadola S, et al: Pregnancy induces numerical and functional changes of CD4 + CD25 high regulatory T cells in patients with rheumatoid arthritis. Ann Rheum Dis 67(7):984, 2008

Friedman DM, Kim MY, Copel JA, et al: Prospective evaluation of fetuses with autoimmune associated congenital heart block followed in the PR interval and dexamethasone evaluation (PRIDE) study. Am J Cardiol 103(8):1102, 2009

Gayed M, Gordon C: Pregnancy and rheumatic diseases. Rheumatology 46: 1634, 2007

Giannakopoulos B, Krilis SA: The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033, 2013

Goodman R, Dellaripa PF, Miller AL, et al: An unusual case of abdominal pain. N Engl J Med 370:70, 2014

Guthrie KA, Dugowson CE, Voigt LF, et al: Does pregnancy provide vaccine-like protection against rheumatoid arthritis? Arthritis Rheum 62(7):1842, 2010

Gutierrez G, Dagnino R, Mintz G: Polymyositis/dermatomyositis and pregnancy. Arthritis Rheum 27:291, 1984

Haddow JE, Rote NS, Dostaljohnson D, et al: Lack of an association between late fetal death and antiphospholipid antibody measurements in the 2nd trimester. Am J Obstet Gynecol 165:1308, 1991

Hahn BH: Systemic Lupus Erythematosus. In Longo DL, Fauci AS, Kasper DL, et al, (eds): Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012

Hamed HO, Ahmed SR, Alzolibani A, et al: Does cutaneous lupus erythematosus have more favorable pregnancy outcomes than systemic disease? A two-center study. Acta Obstet Gynecol Scand 92(8):934, 2013

Hanly JG, Gladman DD, Rose TH, et al: Lupus pregnancy: a prospective study of placental changes. Arthritis Rheum 31:358, 1988

Harris EN: Antirheumatic drugs in pregnancy. Lupus 11:683, 2002

Harris EN, Gharavi AE, Patel SP, et al: Evaluation of the anti-cardiolipin antibody test: report of an international workshop. Clin Exp Immunol 68:215, 1987a

Harris EN, Hughes GRV: Standardizing the anticardiolipin antibody-test. Lancet 1:277, 1987b

Harris EN, Spinnato JA: Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 165:1272, 1991

Häupl T, Østensen M, Grützkau A, et al: Interaction between rheumatoid arthritis and pregnancy: correlation of molecular data with clinical disease activity measures. Rheumatology (Oxford) 47(Supp l):19, 2008a

Häupl T, Østensen M, Grützkau A, et al: Reactivation of rheumatoid arthritis after pregnancy: increased phagocyte and recurring lymphocyte gene activity. Arthritis Rheum 58(10):2981, 2008b

Hazes JMW, Dijkmans BAC, Vandenbroucke JP, et al: Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum 33:1770, 1990

Heilmann L, von Tempelhoff GF, Pollow K: Antiphospholipid syndrome in obstetrics. Clin Appl Thromb Hemost 9:143, 2003

Hernández-Pacheco JA, Estrada-Altamirano A, Valenzuela-Jirón A, et al: Takayasu’s arteritis in pregnancy: report of seven cases. Ginecol Obstet Mex 79(3):143, 2011

Hidaka N, Yamanaka Y, Fujita Y, et al: Clinical manifestations of pregnancy in patients with Takayasu arteritis: experience from a single tertiary center. Arch Gynecol Obstet 285(2):377, 2012

Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725, 1997

Hojnik M, George J, Ziporen L, et al: Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93:1579, 1996

Holers VM, Girardi G, Mo L, et al: Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195:211, 2002

Hom G, Graham RR, Modrek B, et al: Association of systemic lupus erythematosus with C8orf13—BLK and ITGAM—ITGAX. N Engl J Med 358:900, 2008

Hot A, Perard L, Coppere B, et al: Marked improvement of Churg-Strauss vasculitis with intravenous gamma globulins during pregnancy. Clin Rheumatol 26(12):2149, 2007

Huong DLT, Wechsler B, Vauthier-Brouzes D, et al: Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis 60:599, 2001

Hwang I, Lee CK, Yoo B, et al: Necrotizing villitis and decidual vasculitis in the placentas of mothers with Behçet disease. Hum Pathol 40(1):135, 2009

Imbasciati E, Tincani A, Gregorini G, et al: Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 24(2):519, 2009

Iwasawa Y, Kawana K, Fujii T, et al: A possible coagulation-independent mechanism for pregnancy loss involving β(2) glycoprotein 1-dependent antiphospholipid antibodies and CD1d. Am J Reprod Immunol 67(1):54, 2012

Izmirly PM, Saxena AM, Kim MY, et al: Maternal and fetal factors associated with mortality and morbidity in a multi–racial/ethnic registry of anti-SSA/Ro–associated cardiac neonatal lupus. Circulation 124:1927, 2011

Jadaon J, Shushan A, Ezra Y, et al: Behçet’s disease and pregnancy. Acta Obstet Gynecol Scand 84:939, 2005

Jimenez SA, Artlett CM: Microchimerism and systemic sclerosis. Curr Opin Rheumatol 17:86, 2005

Johnson KL, McAlindon TE, Mulcahy E, et al: Microchimerism in a female patient with systemic lupus erythematosus. Arthritis Rheum 44:2107, 2001

Johnston SL, Lock RJ, Gompels MM: Takayasu arteritis: a review. J Clin Pathol 55:481, 2002

Joven BE, Almodovar R, Carmona L, et al: Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 39(4):285, 2010

Julkunen H, Kurki P, Kaaja R, et al: Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis Rheum 36(11):1588, 1993

Kaplan D: Fetal wastage in patients with rheumatoid arthritis. J Rheumatol 13:875, 1986

Kayatas S, Asoglu MR, Selcuk S, et al: Pregnancy in a patient with Wegener’s granulomatosis: a case report. Bull NYU Hosp Jt Dis 70(2):127, 2012

Keeling SO, Oswald AE: Pregnancy and rheumatic disease: “By the book” or “by the doc.” Clin Rheumatol 28(1):1, 2009

Khamashta MA, Ruiz-Irastorza G, Hughes GRV: Systemic lupus erythematosus flares during pregnancy. Rheum Dis Clin North Am 23:15, 1997

Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333(3):142, 1995

Klipple GL, Cecere FA: Rheumatoid arthritis and pregnancy. Rheum Dis Clin North Am 15:213, 1989

Knevel R, de Rooy DP, Zhernakova A, et al: Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 65(7):1684, 2013

Koukoura O, Mantas N, Linardakis H, et al: Successful term pregnancy in a patient with Wegener’s granulomatosis: case report and literature review. Fertil Steril 89:457.e1, 2008

Kozora E, Arciniegas DB, Filley CM, et al: Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum 59:1639, 2008

Kraemer B, Abele H, Hahn M, et al: A successful pregnancy in a patient with Takayasu’s arteritis. Hypertens Pregnancy 27(3):247, 2008

Kuriya B, Hernández-Díaz S, Liu J, et al: Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63(5):721, 2011

Kurkó J, Besenyei T, Laki J, et al: Genetics of rheumatoid arthritis—a comprehensive review. Clin Rev Allergy Immunol 45(2):170, 2013

Kwak-Kim J, Agcaoili MSL, Aleta L, et al: Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am J Reprod Immunol 69(6):596, 2013

Lambe M, Bjornadal L, Neregard P, et al: Childbearing and the risk of scleroderma: a population-based study in Sweden. Am J Epidemiol 159:162, 2004

Lambert NC: Microchimerism in scleroderma: ten years later. Rev Med Interne 31(7):523, 2010

Langen ES, Chakravarty EF, Liaquat M, et al: High rate of preterm birth in pregnancies complicated by rheumatoid arthritis. Am J Perinatol 31(1):9, 2014

Langford C, Kerr G: Pregnancy in vasculitis. Curr Opin Rheumatol 14:36, 2002

Langford CA, Fauci AS: The vasculitis syndromes. In Longo DL, Fauci AS, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012

Lateef A, Petri M: Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol 8(12):710, 2012

Lee ES, Bou-Gharios G, Seppanen E, et al: Fetal stem cell microchimerism: natural-born healers or killers? Mol Hum Reprod 16(11):869, 2010

Lee LA, Weston WL: New findings in neonatal lupus syndrome. Am J Dis Child 138:233, 1984

Lee JY, Huerta PT, Zhang J, et al: Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med 15(1):91, 2009

Levy RA, Vilela VS, Cataldo MJ, et al: Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:401, 2001

Lin MW, Ho JW, Harrison LC, et al: An antibody-based leukocyte-capture microarray for the diagnosis of systemic lupus erythematosus. PLoS One 8(3):e58199, 2013

Linardaki G, Cherouvim E, Goni G, et al: Intravenous immunoglobulin treatment for pregnancy-associated dermatomyositis. Rheumatol Int 31(1):113, 2011

Lissauer DM, Piper KP, Moss PA, et al: Fetal microchimerism: the cellular and immunological legacy of pregnancy. Expert Rev Mol Med 11:e33, 2009

Liu XL, Xiao J, Zhu F: Anti-β2 glycoprotein I antibodies and pregnancy outcome in antiphospholipid syndrome. Acta Obstet Gynecol Scand 92(2):234, 2013

Lockshin MD: Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 32:665, 1989

Lockshin M, Sammaritano L: Lupus pregnancy. Autoimmunity 36:33, 2003

Lockshin MD, Bonfa E, Elkon K, et al: Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus. Arthritis Rheum 31:697, 1988

Lockshin MD, Druzin ML: Rheumatic disease. In Barron WM, Lindheimer JD (eds): Medical Disorders During Pregnancy, 2nd ed. St. Louis, Mosby, 1995, p 307

Lockshin MD, Sammaritano LR: Rheumatic disease. In Barron WM, Lindheimer MD (eds): Medical Disorders During Pregnancy, 3rd ed. St. Louis, Mosby, 2000, p 355

Lockwood CJ, Romero R, Feinberg RF, et al: The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 161:369, 1989

Loeys B, Nuytinck L, Van Acker P, et al: Strategies for prenatal and preimplantation genetic diagnosis in Marfan syndrome (MFS). Prenat Diagn 22:22, 2002

Lubbe WF, Liggins GC: The lupus-anticoagulant: clinical and obstetric complications. NZ Med J 97:398, 1984

Lyra TG, Pinto VA, Ivo FA, et al: Osteogenesis imperfecta in pregnancy. Case report. Rev Bras Anestesiol 60(3):321, 2010

Madazli R, Yuksel MA, Oncul M, et al: Obstetric outcomes and prognostic factors of lupus pregnancies. Arch Gynecol Obstet 289:49, 2014

Makol A, Wright K, Amin S: Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs 71(15):1973, 2011

Mandal D, Mandal S, Dattaray C, et al: Takayasu arteritis in pregnancy: an analysis from eastern India. Arch Gynecol Obstet 285(3):567, 2012

McGeachy C, Lam J: Anti-RNP neonatal lupus in a female newborn. Lupus 18(2):172, 2009

McInnes IB, Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205, 2011

Meroni PL, Borghi MO, Raschi E, et al: Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7(6):330, 2011

Miyakis S, Lockshin MD, Atsumi T, et al: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295, 2006

Moodley J, Ramphal SR, Duursma J, et al: Antiphospholipid antibodies in eclampsia. Hypertens Pregnancy 14:179, 1995

Moroni G, Ponticelli C: Pregnancy after lupus nephritis. Lupus 14:89, 2005

Moroni G, Quaglini S, Banfi G, et al: Pregnancy in lupus nephritis. Am J Kidney Dis 40:713, 2002

Moroni G, Ventura D, Riva P, et al: Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 43:28, 2004

Motta M, Lachassinne E, Boffa MC, et al: European registry of infants born to mothers with antiphospholipid syndrome: preliminary results. Minerva Pediatr 62(3 Suppl 1):25, 2010

Moutsopoulos HM, Vlachoylannopoulos PG: Antiphospholipid antibody syndrome. In Longo DL, Fauci AS, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012, p 2736

Munoz-Suano A, Kallikourdis M, Sarris M, e al: Regulatory T cells protect from autoimmune arthritis during pregnancy. J Autoimmun 38(2–3):J103, 2012

Murray S, Shamsuddin W, Russell R: Sequential combined spinal-epidural for caesarean delivery in osteogenesis imperfecta. Int J Obstet Anesth 19(1):127, 2010

Musiej-Nowakowska E, Ploski R: Pregnancy and early onset pauciarticular juvenile chronic arthritis. Ann Rheum Dis 58:475, 1999

Nelson JL, Hughes KA, Smith AG, et al: Maternal–fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 329:466, 1993

Nelson JL, Østensen M: Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 23:195, 1997

Nelson JL, Voigt LF, Koepsell TD, et al: Pregnancy outcome in women with rheumatoid arthritis before disease onset. J Rheumatol 19:18, 1992

Nodler J, Moolamalla SR, Ledger EM, et al: Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth 9(1):11, 2009

Numano F, Kobayashi Y: Takayasu arteritis—beyond pulselessness. Intern Med 38:226, 1999

Ogunyemi D, Ku W, Arkel Y: The association between inherited thrombophilia, antiphospholipid antibodies and lipoprotein A levels with obstetrical complications in pregnancy. J Thromb Thrombolysis 14:157, 2002

Ohno T, Imai A, Tamaya T: Successful outcomes of pregnancy complicated with dermatomyositis. Gynecol Obstet Invest 33:187, 1992

Ojeda-Uribe M, Afif N, Dahan E, et al: Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 32(5):695, 2013

Oshiro BT, Silver RM, Scott JR, et al: Antiphospholipid antibodies and fetal death. Obstet Gynecol 87:489, 1996

Østensen M: Pregnancy in patients with a history of juvenile rheumatoid arthritis. Arthritis Rheum 34:881, 1991

Østensen M, Villiger PM: The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol 29:185, 2007

Ottaviani G, Lavezzi AM, Rossi L, et al: Sudden unexpected death of a term fetus in an anticardiolipin-positive mother. Am J Perinatol 21:79, 2004

Owen J, Hauth JC: Polyarteritis nodosa in pregnancy: a case report and brief literature review. Am J Obstet Gynecol 160:606, 1989

Pagnoux C, Le Guern V, Goffinet F, et al: Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. Rheumatology (Oxford) 50(5):953, 2011

Papadopoulos NG, Alamanos Y, Voulgari PV, et al: Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 23(6):861, 2005

Papakonstantinou K, Hasiakos D, Kondi-Paphiti A: Clinicopathology of maternal scleroderma. Int J Gynaecol Obstet 99(3):248, 2007

Papapetropoulos T, Kanellakopoulou N, Tsibri E, et al: Polymyositis and pregnancy: report of a case with three pregnancies. J Neurol Neurosurg Psychiatry 64:406, 1998

Partlett R, Roussou E: The treatment of rheumatoid arthritis during pregnancy. Rheumatol Int 31(4):445, 2011

Pattison NS, Chamley LW, McKay EJ, et al: Antiphospholipid antibodies in pregnancy—prevalence and clinical associations. Br J Obstet Gynecol 100:909, 1993

Peart E, Clowse ME: Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol January 10, 2014 [Epub ahead of print]

Pepin M, Schwarze U, Superti-Furga A, et al: Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 342:673, 2000

Petri M: Pregnancy in SLE. Baillières Clin Rheumatol 12:449, 1998

Petri M, Kim MY, Kalunian KC, et al: Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550, 2005

Petri M, The Hopkins Lupus Pregnancy Center: Ten key issues in management. Rheum Dis Clin North Am 33:227, 2007

Pierro E, Cirino G, Bucci MR, et al: Antiphospholipid antibodies inhibit prostaglandin release by decidual cells of early pregnancy: possible involvement of extracellular secretory phospholipase A2. Fertil Steril 71:342, 1999

Pikwer M, Bergström U, Nilsson JA, et al: Breast feeding, but not use of oral contraceptives, is associated with a reduced risk of rheumatoid arthritis. Ann Rheum Dis 68(4):526, 2009

Polzin WJ, Kopelman JN, Robinson RD, et al: The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol 78:1108, 1991

Porter TF, LaCoursiere Y, Scott JR: Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2:CD000112, 2006

Prockop DJ, Bateman JF: Heritable disorders of connective tissue. In Longo DL, Fauci AS, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012

Rai RS, Clifford K, Cohen H, et al: High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 10:3301, 1995

Rak JM, Maestroni L, Balandraud C, et al: Transfer of the shared epitope through microchimerism in women with rheumatoid arthritis. Arthritis Rheum 60(1):73, 2009a

Rak JM, Pagni PP, Tiev K, et al: Male microchimerism and HLA compatibility in French women with scleroderma: a different profile in limited and diffuse subset. Rheumatology 48(4):363, 2009b

Rand JH, Wu XX, Andree HAM, et al: Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood 92:1652, 1998

Rand JH, Wu XX, Andree HAM, et al: Pregnancy loss in the antiphospholipid antibody syndrome—a possible thrombogenic mechanism. N Engl J Med 337:154, 1997a

Rand JH, Wu XX, Guller S, et al: Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 177:918, 1997b

Ranque B, Mouthon L: Geoepidemiology of systemic sclerosis. Autoimmun Rev 9(5):A311, 2010

Raza SH, Pattanaik D, Egerman RS: Painful, swollen hands in a young woman. Obstet Gynecol 116(4):983, 2010

Rein AJ, Mevorach D, Perles Z, et al: Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 119(14):1867, 2009

Ritchie J, Smyth A, Tower C, et al: Maternal deaths in women with lupus nephritis: a review of published evidence. Lupus 21(5):534, 2012

Robertson B, Greaves M: Antiphospholipid syndrome: An evolving story. Blood Reviews 20:201, 2006

Robinson DP, Klein SL: Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav 62(3):263, 2012

Roque H, Paidas M, Rebarber A, et al: Maternal thrombophilia is associated with second- and third-trimester fetal death. Am J Obstet Gynecol 184:S27, 2001

Rosenzweig BA, Rotmensch S, Binette SP, et al: Primary idiopathic polymyositis and dermatomyositis complicating pregnancy: diagnosis and management. Obstet Gynecol Surv 44:162, 1989

Rubin RL: Drug induced lupus. In Wallace DJ, Hahn BH (eds): Dubois’ Lupus Erythematosus, 5th ed. Baltimore, Williams & Wilkins, 1997, p 871

Rudd NL, Nimrod C, Holbrook KA, et al: Pregnancy complications in type IV Ehlers-Danlos Syndrome. Lancet 1(8314–5):50, 1983

Ruiz-Irastorza G, Khamashta MA, Gordon C, et al: Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. Arthritis Rheum 51:78, 2004

Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al: A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353:2539, 2005

Sanna G, Bertolaccini ML, Cuadrado MJ: Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 42:200, 2003

Savi C, Villa L, Civardi L, et al: Two consecutive cases of type A aortic dissection after delivery. Minerva Anestesiol 73:381, 2007

Schoenhoff F, Schmidli J, Czerny M, et al: Management of aortic aneurysms in patients with connective tissue disease. J Cardiovasc Surg 54(1 suppl 1):125, 2013

Scott JR: Risks to the children born to mothers with autoimmune diseases. Lupus 11:655, 2002

Shah A, St. Clair EW: Rheumatoid arthritis. In Longo DL, Fauci AS, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012, p 2738

Sharma BK, Jain S, Vasishta K: Outcome of pregnancy in Takayasu arteritis. Int J Cardiol 75:S159, 2000

Sherer Y, Gorstein A, Fritzler MJ, et al: Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34(2):501, 2004

Shi W, Chong BH, Hogg PJ, et al: Anticardiolipin antibodies block the inhibition by β2 glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 70:342, 1993

Shinohara K, Miyagawa S, Fujita T, et al: Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol 93:952, 1999

Silman A, Kay A, Brennan P: Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 35:152, 1992

Silver RM, Branch DW: Autoimmune diseases in pregnancy: systemic lupus erythematosus and antiphospholipid syndrome. Clin Perinatol 24:91, 1997

Silver RM, Parker CB, Reddy UM, et al: Antiphospholipid antibodies in stillbirth. Obstet Gynecol 122(3):641, 2013

Simchen MJ, Goldstein G, Lubetsky A, et al: Factor V Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 40(1):65, 2009

Simpson JL: Cell-free fetal DNA and maternal serum analytes for monitoring embryonic and fetal status. Fertil Steril 99(4):1124, 2013

Sitar G, Brambati B, Baldi M, et al: The use of non-physiological conditions to isolate fetal cells from maternal blood. Exp Cell Res 302:153, 2005

Skomsvoll JF, Baste V, Irgens LM, et al: The recurrence risk of adverse outcome in the second pregnancy in women with rheumatic disease. Obstet Gynecol 100:1196, 2002

Sneller MC: Wegener’s granulomatosis. JAMA 273:1288, 1995

Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071, 2005

Solomons J, Coucke P, Symoens S, et al: Dermatosparaxis (Ehlers-Danlos Type VIIC): prenatal diagnosis following a previous pregnancy with unexpected skull fractures at delivery. Am J Med Genet A 161(5):1122, 2013

Sorokin Y, Johnson MP, Rogowski N, et al: Obstetric and gynecologic dysfunction in the Ehlers–Danlos syndrome. J Reprod Med 39:281, 1994

Spinillo A, Veneventi F, Epis OM, et al: The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome. Am J Obstet Gynecol 199(6):632.e1, 2008

Srivatsa B, Srivatsa S, Johnson K, et al: Microchimerism of presumed fetal origin in thyroid specimens from women: a case-control study. Lancet 358:2034, 2001

Steen VD: Pregnancy in women with systemic sclerosis. Obstet Gynecol 94:15, 1999

Steen VD, Conte C, Day N, et al: Pregnancy in women with systemic sclerosis. Arthritis Rheum 32:151, 1989

Stirnemann J, Fain O, Lachassinne E, et al: Neonatal lupus erythematosus. Presse Med 31(30):1407, 2002

Stojan G, Baer AN: Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 8(5):439, 2012

Sykes B, Ogilvie D, Wordsworth P, et al: Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet 46(2):293, 1990

Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):127, 1982

Taraborelli M, Ramoni V, Brucato A, et al: Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. Arthritis Rheum 64(6):1970, 2012

Tashkin DP, Elashoff R, Clements PJ, et al: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655, 2006

Tayabali S, Andersen K, Yoong W: Diagnosis and management of Henoch-Schönlein purpura in pregnancy: a review of the literature. Arch Gynecol Obstet 286(4):825, 2012

Tincani A, Rebaioli CB, Andreoli L, et al: Neonatal effects of maternal antiphospholipid syndrome. Curr Rheumatol Rep 11(1):70, 2009

Toglia MR, Weg JG: Venous thromboembolism during pregnancy. N Engl J Med 335:108, 1996

Tower C, Mathen S, Crocker I, et al: Regulatory T cells in systemic lupus erythematosus and pregnancy. Am J Reprod Immunol 69(6):588, 2013

Trudinger BJ, Stewart GJ, Cook C, et al: Monitoring lupus anticoagulant-positive pregnancies with umbilical artery flow velocity waveforms. Obstet Gynecol 72:215, 1988

Tsokos GC: Systemic lupus erythematosus. N Engl J Med 365(22):2110, 2011

Unger A, Kay A, Griffin AJ, et al: Disease activity and pregnancy associated β2-glycoprotein in rheumatoid arthritis. BMJ 286:750, 1983

Vargas J: Systemic sclerosis (scleroderma) and related disorders. In Longo DL, Fauci AS, Kasper DL, et al (eds): Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012, p 2757

Varner MW, Meehan RT, Syrop CH, et al: Pregnancy in patients with systemic lupus erythematosus. Am J Obstet Gynecol 145:1025, 1983

Verstappen SM, King Y, Watson KD, et al: Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(5):823, 2011

Volkov N, Nisenblat V, Ohel G, et al: Ehlers-Danlos syndrome: insight on obstetric aspects. Obstet Gynecol Surv 62:51, 2006

Wagner S, Craici I, Reed D, et al: Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 18(4)342, 2009

Waldorf KM, Nelson JL: Autoimmune disease during pregnancy and the microchimerism legacy of pregnancy. Immunol Invest 37:631, 2008

Wallenius M, Skomsvoll JF, Irgens LM, et al: Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on first birth. Arthritis Rheum 63(6):1534, 2011

Walsh CA, Reardon W, Foley ME: Unexplained prelabor uterine rupture in a term primigravida. Obstet Gynecol 109:455, 2007

Williams L, Chang PY, Park E, et al: Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. Obstet Gynecol 109:561, 2007

Wu H, Birmingham DJ, Rovin B, et al: D-Dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol 3:1628, 2008

Xiao J, Xiong J, Zhu F, et al: Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Ther Med 5(1):287, 2013

Yang W, Tang H, Zhang Y, et al: Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet 92(1):41, 2013

Yasuda M, Takakuwa K, Okinaga A, et al: Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 86:555, 1995

Ye Y, van Zyl B, Varsani H, et al: Maternal microchimerism in muscle biopsies from children with juvenile dermatomyositis. Rheumatology (Oxford) 51(6): 987, 2012

Yeste A, Quintana FJ: Antigen microarrays for the study of autoimmune diseases. Clin Chem 59(7):1036, 2013

Zangari M, Lockwood CJ, Scher J, et al: Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies. Thromb Res 85:177, 1997

Zhao C, Zhao J, Huang Y, et al: New-onset systemic lupus erythematosus during pregnancy. Clin Rheumatol 32(6):815, 2013